D (2010-2018)

STUDIES ON CONDITIONS and RELATED ARTICLES 2010-2018

*Articles/Studies in Pre-2000 List
+Articles/Studies in 2000-2009 List
>Information in Another Section

>DENTISTRY (See TEETH)
DEPRESSION*+
DERMATITIS*+
>DEVIC’S DISEASE (See NEUROMYELITIS OPTICA)
DIABETES +
DIARRHEA
DOWN SYNDROME +
DRIVING AND CANNABIS*+
>DRUG INTERACTIONS (See INTERACTIONS WITH OTHER DRUGS)
DRUG TESTING*+
DRUG TESTING-ATMOSPHERIC
DRUG TESTING-BLOOD/PLASMA*+
DRUG TESTING-BREATH TEST
DRUG TESTING–DETECTION OF DRUGS
DRUG TESTING–DIY CANNABINOID TESTING
DRUG TESTING-EDIBLES
DRUG TESTING-HAIR*+
DRUG TESTING-INFANTS
DRUG TESTING-OTHER*+
DRUG TESTING-ORAL +
DRUG TESTING-POSTMORTEM
DRUG TESTING-QUALITY CONTROL (See Also SAFETY-ADULTERANTS)
>DRUG TESTING-SECOND-HAND SMOKE (See Also METHODS OF USE-SECOND HAND SMOKE)
DRUG TESTING-URINE*+
DRUG TESTING-WASTEWATER/SEWAGE
>DUPUYTREN’S CONTRACTURE + (See News Section)
DYSAUTONOMIC SYNDROME (Describes Several Malfunctions of Autonomic Nervous System; Includes Postural Orthostatic Tachycardia Syndrome [POTS], Multiple System Atrophy, Autonomic Failure and Autonomic Neuropathy)
DYSKINESIA*+
DYSPEPSIA*+
DYSTONIA*+
top


DEPRESSION*+
The use of Cannnabidiol (CBD) to Reduce Insomnia and the Urge To Use Alcohol in a Geriatric person in on going Behavior Therapy (case report–undated) http://cannabisclinicians.org/view-all-case-reports/entry/420/?pagenum=2
The use of Cannnabidiol (CBD) and Meditation to reduce Binge Drinking, Anxiety and to improve Emotional Regulation in Long Term Behavior Therapy (case report–undated) http://cannabisclinicians.org/view-all-case-reports/entry/437/?pagenum=2
Mixed mood disorder (case report–undated) http://cannabisclinicians.org/view-all-case-reports/entry/228/?pagenum=2
Harm Reduction: Alcohol Use Disorder, Cannabis-induced Psychotic Disorder and a tale of two Hemp Oils, in a Patient diagnosed with a Cluster A & B Personality Disorders in Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2866040/?tool=pubmed
Uni-Morbid and Co-Occurring Marijuana and Tobacco Use: Examination of Concurrent Associations with Negative Mood States (full–2010)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861285/?tool=pubmed
Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders? (full–2010)
http://www.scielo.br/pdf/rbp/v32s1/en_a04v32s1.pdf
Deficiency in Endocannabinoid Signaling in the Nucleus Accumbens Induced by Chronic Unpredictable Stress (full-2010)
http://www.nature.com/npp/journal/v35/n11/full/npp201099a.html
Depression-resistant endophenotype in mice overexpressing cannabinoid CB2 receptors (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936848/?report=classic
The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism (full–2010) http://www.mdpi.com/1424-8247/3/8/2647/htm
Brain CB2 Receptors: Implications for Neuropsychiatric Disorders (link to PDF–2010) http://www.mdpi.com/1424-8247/3/8/2517
Therapeutical use of the cannabinoids in psychiatry (full–2010)  http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462010000500009&lng=en&nrm=iso&tlng=en
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant
in overweight and obese patients with type 2 diabetes (full–2010)  http://onlinelibrary.wiley.com/doi/10.1111/j.1463-1326.2009.01188.x/full
Information for Health Care Professionals- Marihuana (marijuana, cannabis) dried plant
for administration by ingestion or other means (Health Canada) (full–2010)  http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php
Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A  receptors (full–2010) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823358/
Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers (full–2010)  https://academic.oup.com/ijnp/article/13/8/1103/809017
A model of endocannabinoid 2-AG-mediated depolarization-induced suppression of
inhibition (article–2010) http://www.biomedcentral.com/content/pdf/1471-2202-11-S1-P189.pdf
Genes differentially expressed in CB1 knockout mice: involvement in the depressive-like phenotype (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20692131
Control of bone remodeling by nervous system. Nervous system and bone (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/21123931
Gadolinium-HU-308-incorporated micelles (full–2011) http://www.ncbi.nlm.nih.gov/books/NBK54067/pdf/CB2R-Gd-Micelles.pdf
Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085542/
N-palmitoylethanolamide, an endocannabinoid, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice (full–2011) http://www.if-pan.krakow.pl/pjp/pdf/2011/3_834.pdf
Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21278728
top
Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Figure 1: n-3/n-6 PUFA dietary imbalance alters PUFAs level in mouse brain (charts–2011) http://www.nature.com/neuro/journal/v14/n3/fig_tab/nn.2736_F1.html
Neuropsychiatric adverse effects of centrally acting antiobesity drugs (1st page–2011)  https://www.deepdyve.com/lp/wiley/neuropsychiatric-adverse-effects-of-centrally-acting-antiobesity-drugs-Sy0a9pYcBp
Endocannabinoid system dysfunction in mood and related disorders (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21916860
Intense exercise increases circulating endocannabinoid and BDNF levels in humans—Possible implications for reward and depression (abst–2011)
http://www.psyneuen-journal.com/article/PIIS0306453011002873/abstract?rss=yes
Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21497918
Cannabinoids and emotionality: a neuroanatomical perspective (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21827834
Medical cannabis use in post-traumatic stress disorder: a naturalistic observational study (abst–2011) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=481
High on Life? Medical Marijuana Laws and Suicide (full–2012) http://ftp.iza.org/dp6280.pdf
Serum contents of endocannabinoids are correlated with blood pressure in depressed women (full–2012) http://www.lipidworld.com/content/pdf/1476-511X-11-32.pdf
Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts (full–2012) http://www.biomedcentral.com/1471-244X/12/112
Cannabinoid Receptor Genotype Moderation of the Effects of Childhood Physical Abuse on Anhedonia and Depression (full–2012)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706194/
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481531/
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities (full–2012)
http://rstb.royalsocietypublishing.org/content/367/1607/3353.full?sid=1569c370-cd5c-4358-89ff-857201f5e069
The combined effects of parental divorce and parental history of depression on cannabis
use in young adults in France (link to PDF–2012) https://hal.archives-ouvertes.fr/inserm-00708161
Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes (full–2012) http://journals.sagepub.com/doi/full/10.1177/0269881112454229
Effect of delta-9-tetrahydrocannabinol on behavioral despair and on presynaptic and postsynaptic serotonergic transmission (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22386778
Nature Against Depression (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22414105
Lower levels of cannabinoid 1 receptor mRNA in female eating disorder patients: Association with wrist cutting as impulsive self-injurious behavior (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22542985
Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22534181
top
Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22990678
Essential fatty acids and lipid mediators. Endocannabinoids (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22730630
The CB(1) Receptor-Mediated Endocannabinoid Signaling and NGF: The Novel Targets of Curcumin (turmeric) (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22311129
Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical
and neurobiological evidence (abst–2012)  http://www.ncbi.nlm.nih.gov/pubmed/22736575
Glucocorticoid-endocannabinoid interaction in cardiac surgical patients: relationship to
early cognitive dysfunction and late depression (abst–2012)  http://www.degruyter.com/abstract/j/revneuro.2012.23.issue-5-6/revneuro-2012-0058/revneuro-2012-0058.xml?rskey=jSEJyD&result=10&q=cannabinoid
Effect of dietary fat type on anxiety-like and depression-like behavior in mice (full–2013) http://www.springerplus.com/content/2/1/165
Cannabinoids, Neurogenesis and Antidepressant Drugs: Is there a Link? (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648779/
Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses (full–2013) http://www.biolmoodanxietydisord.com/content/3/1/19
Endocannabinoid system and mood disorders: Priming a target for new therapies (full–2013) http://www.sciencedirect.com/science/article/pii/S0278584612002801
A Randomized Double-blind, Placebo Controlled Trial of Venlafaxine-Extended Release for Co-occurring Cannabis Dependence and Depressive Disorders (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636166/
Low frequency stimulation evokes serotonin release in the nucleus accumbens and induces long-term depression via production of endocannabinoid (full-2013) http://jn.physiology.org/content/111/5/1046.long
The effects of anandamide signaling enhanced by the FAAH inhibitor URB597 on coping styles in rats (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830591/
The endocannabinoid system and emotional processing: A pharmacological fMRI study with ∆9-tetrahydrocannabinol (full–2013) http://www.europeanneuropsychopharmacology.com/article/S0924-977X%2813%2900195-8/fulltext
Cannabinoid Receptor Activation Prevents the Effects of Chronic Mild Stress on Emotional Learning and LTP in a Rat Model of Depression (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924526/
Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002665/
The neuroprotective effects of cocoa flavanol and its influence on cognitive performance (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575938/
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies (full–2013) http://www.karger.com/Article/FullText/350094
Can Marijuana Reduce Social Pain? (full–2013) http://journals.sagepub.com/doi/full/10.1177/1948550613488949
Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment (abst–2013) http://link.springer.com/article/10.1007%2Fs00213-013-2995-y
Additive effect of rimonabant and citalopram on extracellular serotonin levels monitored with in vivo microdialysis in rat brain (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23562616
Entopeduncular nucleus endocannabinoid system modulates sleep-waking cycle and mood in rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23584096
Sleep Quality Moderates the Relation between Depression Symptoms and Problematic Cannabis Use among Medical Cannabis Users (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23721537
Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23844686
The endocannabinoid system and its possible role in neurobiology of psychiatric disorders (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24326750
Testing bidirectional effects between cannabis use and depressive symptoms: moderation by the serotonin transporter gene (abst–2013) http://onlinelibrary.wiley.com/doi/10.1111/j.1369-1600.2011.00380.x/abstract
top
Effects of the cannabinoid 2 receptor-selective agonist GW405833 in assays of acute
pain-stimulated and paindepressed behavior in rats (abst–2013)
http://www.fasebj.org/content/27/1_Supplement/886.9.abstract?sid=6740ccbc-1f93-4779-b975-a966a2a4ac87
Antidepressants and Changes in Concentration of Endocannabinoids and NAcylethanolamines in Rat Brain Structures (full–2014) http://download.springer.com/static/pdf/559/art%253A10.1007%252Fs12640 -014-9465-0.pdf?auth66=1395868546_998a8d5d87cb02529572689ff9213e4a&ext=.pdf
Genetic Variations in the Human Cannabinoid Receptor Gene Are Associated with Happiness (full–2014) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0093771
Therapeutic benefits of cannabis: a patient survey (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998228/
Effects of chaiyuwendan decoction on endocannabinoids levels in adipose tissue of rats with chronic stress-induced depression (full–2014) http://www.journaltcm.com/modules/Journal/contents/stories/141/16.pdf
Genetic Disruption of 2-Arachidonoylglycerol Synthesis Reveals a Key Role for Endocannabinoid Signaling in Anxiety Modulation (full–2014) http://www.cell.com/cell-reports/fulltext/S2211-1247(14)00955-3
Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates (full–2014) http://www.futuremedicine.com/doi/full/10.2217/pgs.14.151
Therapeutic Potential of Inhibitors of Endocannabinoid Degradation for the Treatment of Stress-Related Hyperalgesia in an Animal Model of Chronic Pain (full–2014) http://www.nature.com/npp/journal/v40/n2/full/npp2014198a.html
Neural Effects of Cannabinoid CB1 Neutral Antagonist Tetrahydrocannabivarin (THCv) on Food Reward and Aversion in Healthy Volunteers (full–2014) http://ijnp.oxfordjournals.org/content/18/6/pyu094.long
Monoacylglycerol Lipase Inhibition Blocks Chronic Stress-Induced Depressive-Like Behaviors via Activation of mTOR Signaling (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023150/
Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain depressed behavior in rats (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963812/
Cannabinoid Transmission in the Prefrontal Cortex Bi-Phasically Controls Emotional Memory Formation via Functional Interactions with the Ventral Tegmental Area (full–2014) http://www.jneurosci.org/content/34/39/13096.long
top
The Endocannabinoid/Endovanilloid System and Depression (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243035/
Relationships between serotonergic and cannabinoid system in depressive-like behavior: a PET study with [11C]-DASB (full–2014) http://onlinelibrary.wiley.com/doi/10.1111/jnc.12716/full
Stress regulates endocannabinoid-CB1 receptor signaling (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247817/
Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696509/
Cannabinoid Type 1 Receptor Availability in the Amygdala Mediates Threat Processing in Trauma Survivors (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207337/
Nutritional omega-3 modulates neuronal morphology in the prefrontal cortex along with depression-related behaviour through corticosterone secretion (full–2014) http://www.nature.com/tp/journal/v4/n9/full/tp201477a.html
Modulation of early stress-induced neurobiological changes: a review of behavioural and pharmacological interventions in animal models (full–2014) http://www.nature.com/tp/journal/v4/n5/full/tp201431a.html
Cannabis use and suicidal ideations in high-school students (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25123343
Anti-depressive mechanism of repetitive transcranial magnetic stimulation in rat: The role of the endocannabinoid system (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24479995
Is there a role for palmitoylethanolamide in the treatment of depression? (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24630855
The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24861565
β-Caryophyllene, a CB2 Receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24930711
Paracetamol potentiates the antidepressant-like and anticompulsive-like effects of fluoxetine (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25340977
The association between cannabis use and mood disorders: A longitudinal study (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/25451420
Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other  oxygenases (abst-2014)  http://www.sciencedirect.com/science/article/pii/S1388198114002674
Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24923339
Blockade of 2-arachidonoylglycerol hydrolysis produces antidepressant-like effects and enhances adult hippocampal neurogenesis and synaptic plasticity (full–2015) http://onlinelibrary.wiley.com/doi/10.1002/hipo.22344/full
High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity (full–2015) http://ijnp.oxfordjournals.org/content/early/2015/09/04/ijnp.pyv095.long
Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression? (full–2015) http://link.springer.com/article/10.1007/s00213-015-4105-9/fulltext.html
Chronic Adolescent Marijuana Use as a Risk Factor for Physical and Mental Health Problems in Young Adult Men (full-2015) http://www.ncbi.nlm.nih.gov/pubmed/26237286
Circulating endocannabinoids during hematopoietic stem cell transplantation: A pilot study (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476410/
Mechanisms of stress in the brain (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933289/
Cannabis use, depression and anxiety: A 3-year prospective population-based study (link to PDF–2015) http://www.jad-journal.com/article/S0165-0327%2815%2931030-2/abstract
Cannabis in cancer care (full–2015) http://escholarship.org/uc/item/6367m6vj#page-1
Endocannabinoid Modulation of Predator Stress-Induced Long-Term Anxiety in Rats  (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793117/
Cannabinoid Receptors May Control Aversive Memories (abstract & news-2015)  http://neurosciencenews.com/habenula-cb1-receptors-memory-2742/
Differential proteomic analysis of the anti-depressive effects of oleamide in a rat chronic mild stress model of depression (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25641667
Involvement of norepinephrine and serotonin system in antidepressant-like effects of oleoylethanolamide in the mice models of behavior despair (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25778418
top
The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs-A practical view (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25791296
For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders (abst–2015) http://www.sciencedirect.com/science/article/pii/S027858461500055X
Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: Mechanism of action and possible interactions with cholinergic system (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25660201
CB1 receptors modulate affective behaviour induced by neuropathic pain (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25863168
Antidepressant-like Effects of Oleoylethanolamide in a Mouse Model of Chronic Unpredictable Mild Stress (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25864425
Smoke Your Troubles Away: Exploring the Effects of Death Cognitions on Cannabis Craving and Consumption (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25950588
The endocannabinoid system role in the pathogenesis of obesity and depression (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26277182
A cannabinoid receptor 1 polymorphism is protective against major depressive disorder in methadone-maintained outpatients (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26331953
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26391492
Endocannabinoids and Mental Disorders (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26408164
Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1
receptor inverse agonist AM-251 after physical stress in mice (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26609670
Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants (abst–2015) http://www.eurekaselect.com/132200/article
Sex-dependence of anxiety-like behavior in cannabinoid receptor 1 (Cnr1) knockout mice (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26684509
The fatty acid amide hydrolase inhibitor URB597 modulates serotonin-dependent emotional behaviour, and serotonin1A and serotonin2A/C activity in the hippocampus (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26747370
Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26711860
top
Mediating processes between stress and problematic marijuana use (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25661989
Maternal age and trajectories of cannabis use (abst–2015)  http://www.drugandalcoholdependence.com/article/S0376-8716%2815%2901662-2/abstract
Monoacylglycerol lipase inhibitors produce pro- or antidepressant responses via hippocampal CA1 GABAergic synapses (full–2016) http://www.nature.com/mp/journal/vaop/ncurrent/full/mp201622a.html
Cyclooxygenase-2 inhibition reduces stress-induced affective pathology (full–2016) https://elifesciences.org/content/5/e14137
Putative Epigenetic Involvement of the Endocannabinoid System in Anxiety- and Depression-Related Behaviors Caused by Nicotine as a Stressor (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942073/
Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects (full–2016) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0158779 Endocannabinoid-Mediated Plasticity in Nucleus Accumbens Controls Vulnerability to Anxiety after Social Defeat Stress (full–2016) http://www.cell.com/cell-reports/fulltext/S2211-1247(16)30851-8
Endocannabinoid signaling in social functioning: an RDoC perspective (full–2016) http://www.nature.com/tp/journal/v6/n9/full/tp2016169a.html
The relationship between cannabis use and measures of anxiety and depression in a sample of college campus cannabis users and non-users post state legalization in Colorado (full–2016) https://peerj.com/articles/2782/
Marijuana Compounds: A Nonconventional Approach to Parkinson’s Disease Therapy (full–2016) https://www.hindawi.com/journals/pd/2016/1279042/
Ketamine and MAG Lipase Inhibitor-Dependent Reversal of Evolving Depressive Behavior during Forced Abstinence from Alcohol Drinking (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26751284
Lipids in psychiatric disorders and preventive medicine (full–2016)  http://www.sciencedirect.com/science/article/pii/S0149763415303353
The association of specific traumatic experiences with cannabis initiation and transition  to problem use: Differences between African-American and European-American women  (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833569/
Target-specific modulation of the descending prefrontal cortex inputs to the dorsal raphe nucleus by cannabinoids (full–2016)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868450/
Endocannabinoid system: Role in depression, reward and pain control (Review) (full–2016) https://www.spandidos-publications.com/10.3892/mmr.2016.5585
The endocannabinoid system and NGF are involved in the mechanism of action of
resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric
disorders (full–2016) http://link.springer.com/article/10.1007/s00213-015-4188-3
Bidirectional Associations Between Cannabis Use and Depressive Symptoms From
Adolescence Through Early Adulthood Among At-Risk Young Men (full–2016)  http://www.ncbi.nlm.nih.gov/pubmed/26997187
Dose-dependent cannabis use, depressive symptoms, and FAAH genotype predict sleep
quality in emerging adults: a pilot study (full–2016)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289074/
Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on
Executive Function (full–2016)  http://journal.frontiersin.org/article/10.3389/fphar.2016.00355/full
The impact of drugs for multiple sclerosis on sleep (full–2016)  http://journals.sagepub.com/doi/full/10.1177/1352458516664034
Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review (link to download–2016) http://www.eurekaselect.com/138787/article
Treating Depression in Alcoholics (news & abst–2016)  http://neurosciencenews.com/alcoholism-depression-psychology-3541/
Marijuana Could Help Treat Drug Addiction and Mental Health Problems (news & abst–2016) http://neurosciencenews.com/addiction-mental-health-marijuana-5536/
Role of hypothalamic cannabinoid receptors in post-stroke depression in rats (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26778127
Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex – possible involvement of 5-HT1A and CB1 receptors (abst–2016) http://www.sciencedirect.com/science/article/pii/S0166432816300298
top
Cannabidiol, neuroprotection and neuropsychiatric disorders (abst–2016) http://www.sciencedirect.com/science/article/pii/S1043661816000396
Placebo effect: clinical, biological and therapeutical involvements in depression (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26879253
Sex and age specific effects of delta-9-tetrahydrocannabinol during the periadolescent period in the rat: The unique susceptibility of the prepubescent animal (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26898326
Sevoflurane Prevents Stroke-induced Depressive and Anxiety Behaviors by Promoting Cannabinoid Receptor Subtype I-dependent Interaction Between β-Arrestin 2 and ERK1/2 in the Rat Hippocampus (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26991409 Gender Differences in Associations Between Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/26903256
Genetically reduced FAAH activity may be a risk for the development of anxiety and depression in persons with repetitive childhood trauma (abst–2016) http://www.europeanneuropsychopharmacology.com/article/S0924-977X(16)00077-8/abstract
Exercise deprivation increases negative mood in exercise-addicted subjects and modifies their biochemical markers (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26812592
Medical marijuana use in head and neck squamous cell carcinoma patients treated with radiotherapy (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27005465
Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27023732
Pharmacological inhibition of FAAH activity in rodents: a promising pharmacological approach for psychological – cardiac comorbidity? (abst–2016) http://www.sciencedirect.com/science/article/pii/S0149763416300318
Association between schizotypal and borderline personality disorder traits, and cannabis use in young adults (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27149691 Prohedonic Effect of Cannabidiol in a Rat Model of Depression (abst–2016) http://www.karger.com/Article/Abstract/443890
Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27262964
New Zealand Health Survey 2012/13: characteristics of medicinal cannabis users (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27349158
Anxiety, depression and risk of cannabis use: Examining the internalising pathway to use among Chilean adolescents (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27427415
The genetic basis of the comorbidity between cannabis use and major depression (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27517884
Anandamide reverses depressive-like behavior, neurochemical abnormalities and oxidative-stress parameters in streptozotocin-diabetic rats: Role of CB1 receptors (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27544303
Contribution of health motive to cannabis use among high-school students (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27543835
Chronic stress leads to epigenetic dysregulation of neuropeptide-Y and cannabinoid CB1 receptor in the mouse cingulate cortex (abst–2016) http://www.sciencedirect.com/science/article/pii/S0028390816304580
Chronic FAAH inhibition during nicotine abstinence alters habenular CB1 receptor activity and precipitates depressive-like behaviors (abst–2016) http://www.sciencedirect.com/science/article/pii/S0028390816304579
Targeting the Endocannabinoid System in Psychiatric Illness (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27811555
Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia (abst–2016) http://www.sciencedirect.com/science/article/pii/S0278584616302524
Sex-dependent influence of chronic mild stress (CMS) on voluntary alcohol consumption; study of neurobiological consequences (abst–2016) http://www.sciencedirect.com/science/article/pii/S0091305716302465
Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27919478
A dual inhibitor of FAAH and TRPV1 channels shows dose-dependent effect on depression-like behaviour in rats (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27938441
Signaling pathways to and from the hypophysial pars tuberalis, an important center for
the control of seasonal rhythms (abst–2016)  https://www.ncbi.nlm.nih.gov/pubmed/28511899
The Anxiolytic Actions of 2-Arachidonoylglycerol: Converging Evidence From Two Recent Genetic Endocannabinoid Deficiency Models (abst–2016)  http://www.biologicalpsychiatryjournal.com/article/S0006-3223(15)00532-6/fulltext
Simvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in
C57BL/6 mice (full–2017) https://www.nature.com/articles/s41598-017-02576-5
Changes in the Brain Endocannabinoid System in Rat Models of Depression (full-2017) http://link.springer.com/article/10.1007%2Fs12640-017-9708-y
Palmitoylethanolamide Reduces Neuropsychiatric Behaviors by Restoring Cortical  Electrophysiological Activity in a Mouse Model of Mild Traumatic Brain Injury (full–2017) http://journal.frontiersin.org/article/10.3389/fphar.2017.00095/full
Endocannabinoid signalling modulates susceptibility to traumatic stress exposure (full–2017) http://www.nature.com/articles/ncomms14782
Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of  Cannabidiol in Psychiatric Disorders (full–2017)  http://journal.frontiersin.org/article/10.3389/fphar.2017.00269/full
Residential Mobility, Transience, Depression, and Marijuana Use Initiation Among
Adolescents and Young Adults (full–2017)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457171/
Adolescent Exposure to the Synthetic Cannabinoid WIN 55212-2 Modifies Cocaine
Withdrawal Symptoms in Adult Mice (full–2017)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486147/
Cannabis as a substitute for prescription drugs – a cross-sectional study (full–2017)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422566/
New drugs in psychiatry: focus on new pharmacological targets (full–2017)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373420/
Abnormalities in Dynamic Brain Activity Caused by Mild Traumatic Brain Injury Are  Partially Rescued by the Cannabinoid Type-2 Receptor Inverse Agonist SMM-189 (full–2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562300/
Targeting the Endocannabinoid/CB1 Receptor System For Treating Major Depression
Through Antidepressant Activities of Curcumin and Dexanabinol-Loaded Solid Lipid
Nanoparticles (full–2017) https://www.karger.com/Article/FullText/480001
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and
Relevant Animal Studies (full–2017)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569602/
Social Isolation in Early versus Late Adolescent Mice Is Associated with Persistent  Behavioral Deficits That Can Be Improved by Neurosteroid-Based Treatment (full–2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581875/
Effects of cannabis use and subclinical depression on the P3 event-related potential in an
emotion processing task (full–2017)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371467/
Selectively Impaired Endocannabinoid-Dependent Long-Term Depression in the Lateral
Habenula in an Animal Model of Depression (full–2017)  http://www.sciencedirect.com/science/article/pii/S221112471730863X
Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference (full–2017)  https://www.nature.com/articles/s41598-017-17796-y
Schizophrenia and depression, two poles of endocannabinoid system deregulation (full–2017) https://www.nature.com/articles/s41398-017-0029-y
Cannabinoid Modulation of the Stressed Hippocampus (full–2017)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742214/
Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist,  rimonabant, on emotional processing (download–2017)  http://www.thcint.com/uploads/1/9/3/7/19371199/2011_7_days_of_treatment.pdf
Cannabis Use in Palliative Oncology: A Review of the Evidence for Popular Indications
(link to PDF–2017) https://www.ima.org.il/IMAJ/ViewArticle.aspx?aId=4043
Cannabis Use and Risk for Substance Use Disorders and Mood or Anxiety Disorders (1st page–2017) http://jamanetwork.com/journals/jama/article-abstract/2610319
FAAH Inhibition Produces Antidepressant-like efforts of Mice to Acute Stress via Synaptic Long-term Depression (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28193523
The effects of synthetic cannabinoids on executive function (abst-2017)  https://www.ncbi.nlm.nih.gov/pubmed/28160034
Activation of cannabinoid receptors elicits antidepressant-like effects in a mouse model
of social isolation stress (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0361923016303100
Associations between substance use disorders and suicide or suicide attempts in people
with mental illness: A Danish nationwide, prospective, register-based study of patients
diagnosed with schizophrenia, bipolar disorder, unipolar depression or personality
disorder (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28192643
Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent  schizophrenia patients versus non-psychiatric controls (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28285022
Cannabinoids as therapeutic for PTSD (abst–2017)  http://www.sciencedirect.com/science/article/pii/S2352250X16302342
Endocannabinoid and Mood Responses to Exercise in Adults with Varying Activity Levels (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28319590
Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of
patients with major depression: a preliminary prospective study (abst–2017)  https://link.springer.com/article/10.1007%2Fs00406-017-0789-7
Cannabis use and the course and outcome of major depressive disorder: A population
based longitudinal study (abst–2017) http://www.psy-journal.com/article/S0165-1781(16)31187-8/abstract
Cannabis use and mental health-related quality of life among individuals with depressive disorders (abst–2017) http://www.psy-journal.com/article/S0165-1781(15)30306-1/fulltext
Role of cannabinoid receptor 1-mediated synaptic plasticity in neuropathic pain and  associated depression (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28364110
Prefrontal endocannabinoids, stress controllability and resilience: A hypothesis (abst–2017) http://www.sciencedirect.com/science/article/pii/S0278584616302470
Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep  (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28372506
Neurosteroid biosynthesis downregulation and changes in GABAA receptor subunit  composition: A biomarker axis in stress-induced cognitive and emotional impairment  (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28456011
Properties of the corticostriatal long term depression induced by medial prefrontal cortex high frequency stimulation in vivo (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0028390817301971
Nucleus Accumbens Functional Connectivity at Age 20 is Associated with Trajectory of
Adolescent Cannabis Use and Predicts Psychosocial Functioning in Young Adulthood  (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28547854
Associations of anxiety sensitivity and emotional symptoms with the subjective effects of
alcohol, cigarettes, and cannabis in adolescents (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28544955
Examination of cumulative effects of early adolescent depression on cannabis and  alcohol use disorder in late adolescence in a community-based cohort (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28600897
User characteristics and effect profile of Butane Hash Oil: An extremely high-potency
cannabis concentrate (abst–2017)  http://www.drugandalcoholdependence.com/article/S0376-8716(17)30255-7/fulltext
Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?  (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28636769
Chronic CB1 cannabinoid receptor antagonism persistently increases dendritic spine  densities in brain regions important to zebra finch vocal learning and production in an  antidepressant-sensitive manner (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28743448
Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28745306
Interferon-γ causes mood abnormalities by altering cannabinoid CB1 receptor function in the mouse striatum (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28757328
Role of orbitofrontal sulcogyral pattern on lifetime cannabis use and depressive
symptoms (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0278584617303676?via%3Dihub
Adolescent peer networks and the moderating role of depressive symptoms on
developmental trajectories of cannabis use (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28738220
CHANGES IN THE CANNABINOIDS RECEPTORS IN RATS FOLLOWING TREATMENT WITH ANTIDEPRESSANTS (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0161813X17301717
Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes,  hippocampal neuroglial reorganization and depression in mice (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28890155
Emotional disorders induced by Hemopressin and RVD-hemopressin(α) administration in rats (abst–2017) http://www.sciencedirect.com/science/article/pii/S1734114017303663?via%3Dihub
Amplification of mGlu5-endocannabinoid signaling rescues behavioral and synaptic  deficits in a mouse model of adolescent and adult dietary polyunsaturated fatty acids  imbalance (abst–2017)  http://www.jneurosci.org/content/early/2017/06/20/JNEUROSCI.3516-16.2017
Marijuana use during pregnancy: A comparison of trends and correlates among married  and unmarried pregnant women (abst–2017)  http://www.drugandalcoholdependence.com/article/S0376-8716(17)30531-8/fulltext
CB1 cannabinoid receptor ligands augment the antidepressant-like activity of biometals
(magnesium and zinc) in the behavioural tests (abst–2018)  https://www.ncbi.nlm.nih.gov/pubmed/29380383
Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and  Related Comorbidities (abst–2018) https://www.ncbi.nlm.nih.gov/pubmed/29372545


DERMATITIS*+
Protective role of palmitoylethanolamide in contact allergic dermatitis (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/19909294
Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20206138
Comparative topical anti-inflammatory activity of cannabinoids and cannabivarins (abst–2010) http://www.sciencedirect.com/science/article/pii/S0367326X10000870
Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/
Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in  health and disease (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624216/
Endocannabinoid signaling and epidermal differentiation (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21628127
Molecular allergology in practice: an unusual case of LTP allergy (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/22360137
Differences in peripheral endocannabinoid modulation of scratching behavior in facial vs spinally-innervated skin (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394407/
The role of CB2 receptor ligands in human eosinophil function (full–2012) http://www.biomedcentral.com/content/pdf/2050-6511-13-S1-A13.pdf
Inhibitory effect of topical adelmidrol on antigen-induced skin wheal and mast cell behavior in a canine model of allergic dermatitis (full–2012) http://www.biomedcentral.com/1746-6148/8/230
Endocannabinoids limit excessive mast cell maturation and activation in human skin (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22226549
Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22738050
Involvement of the endogenous cannabinoid 2 ligand 2-arachidonyl glycerol in allergic  inflammation (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22652530
Cannabinoid 1 Receptors in Keratinocytes Modulate Proinflammatory Chemokine Secretion and Attenuate Contact Allergic Inflammation (full–2013) http://www.jimmunol.org/content/190/10/4929.long
Epigenetic Control of Skin Differentiation Genes by Phytocannabinoids (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23869687
Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23889474
The expression of cannabinoid receptor 1 is significantly increased in atopic patients (full–2014) http://www.jacionline.org/article/S0091-6749%2813%2902936-9/fulltext
Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis (full–2014) http://www.biomedcentral.com/1746-6148/10/21
TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240254/
Cannabinoid 1 receptors in keratinocytes attenuate FITC-induced mouse atopic-like dermatitis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24750433
Harnessing neuroendocrine controls of keratin expression: A new therapeutic strategy for skin diseases? (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24823963
Endocannabinoid signaling at the periphery: 50 years after THC (full–2015)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420685/
Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26095080
top
Adelmidrol increases the endogenous concentrations of palmitoylethanolamide in canine keratinocytes and down-regulates an inflammatory reaction in an in vitro model of contact allergic dermatitis (abst–2015) http://www.sciencedirect.com/science/article/pii/S1090023315004712

Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model (full–2016) http://anndermatol.org/DOIx.php?id=10.5021/ad.2016.28.1.22
N-acyl ethanolamide and eicosanoid involvement in irritant dermatitis (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26947140
Dermatological Aspects of Synthetic Cannabinoid Addiction (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27028361
Anandamide Suppresses Proinflammatory T Cell Responses In Vitro through Type-1 Cannabinoid Receptor-Mediated mTOR Inhibition in Human Keratinocytes (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27694494
Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27720681
Targeting Cutaneous Cannabinoid Signaling in Inflammation – A “High”-way to Heal? (full–2017) http://www.ebiomedicine.com/article/S2352-3964(17)30003-8/fulltext
The Endocannabinoid System and Its Role in Eczematous Dermatoses (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28098721
The Inhibitory Effect of S-777469, a Cannabinoid Type 2 Receptor Agonist, on Skin  Inflammation in Mice (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28214870
Insights into future therapeutics for atopic dermatitis (abst–2018)  https://www.ncbi.nlm.nih.gov/pubmed/29376435


DIABETES/INSULIN +
Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845559/?tool=pmcentrez
Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005548/?tool=pubmed
Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy (full–2010) http://diabetes.diabetesjournals.org/content/59/4/1046.full?sid=0bc8e3fa-5275-4b19-8acc-4aec5dfac384
Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003779/
Cannabinoid Receptors are Coupled to Stimulation of Insulin Secretion from Mouse MIN6 β-cells (full–2010) http://www.karger.com/Article/Pdf/320527
Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients (full-2010) http://www.lipidworld.com/content/9/1/43
Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy (full-2010) http://www.natap.org/2010/newsUpdates/marijuana.pdf
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes (full–2010) http://onlinelibrary.wiley.com/doi/10.1111/j.1463-1326.2009.01188.x/full
Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes? (full–2010) http://www.jci.org/articles/view/44099?search%5Babstract_text%5D=&search%5Barticle_text%5D=cannabinoid&search%5Bauthors_text%5D=&search%5Bfpage%5D=&search%5Btitle_text%5D=&search%5Bvolume%5D=
Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients (full–2010)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868848/?tool=pubmed
Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation (full–2010) http://www.wjgnet.com/1948-9358/full/v1/i1/12.htm
Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution (full–2010) http://www.eje-online.org/content/163/3/407.full
Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways (full–2010) http://diabetes.diabetesjournals.org/content/59/11/2826.full.pdf+html
Modulation of Adipocyte Biology by Δ9-Tetrahydrocannabinol (full-2010)  http://onlinelibrary.wiley.com/doi/10.1038/oby.2010.100/full
Information for Health Care Professionals- Marihuana (marijuana, cannabis) dried plant
for administration by ingestion or other means (Health Canada) (full–2010)  http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php
Expression and function of cannabinoid receptors in mouse islets (download–2010)  http://www.tandfonline.com/doi/pdf/10.4161/isl.2.5.12729
AMELIORATIVE POTENTIAL OF CANNABIS SATIVA EXTRACT ON DIABETES INDUCED NEUROPATHIC PAIN IN RATS (full–2010) http://www.ijpsr.com/V1I11/11%20Vol%201,%20Issue%2011,%20IJPSR,%20Paper%206.pdf
top
A randomised, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GW42003 : GW42004 plus GW42003 and GW42004 alone in the treatment of dyslipidaemia in subjects with Type 2 diabetes (research summary–2010) http://www.hra.nhs.uk/news/research-summaries/gwmd1092-gw42003gw42004-together-plus-alone-intype-ii-diabetes/#sthash.FT2P6YcB.dpuf
American Diabetes Association–70th scientific sessions–research on novel therapeutics: part 2 (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20799137
Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20936991
Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20937249
AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20816753
Endocannabinoid (EC) Receptor, CB1, and EC Enzymes’ Expression in Primary Adipocyte Cultures of Lean and Obese Pre-pubertal Children in Relation to Adiponectin and Insulin (abst–2010) http://www.degruyter.com/abstract/j/jpem.2010.23.issue-10/jpem.2010.162/jpem.2010.162.xml?rskey=38kdx0&result=22&q=cannabinoid
G1359A polymorphism in the cannabinoid receptor-1 gene is associated with metabolic syndrome in the Chinese Han population (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20851297
GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/21094910
Nonalcoholic fatty liver disease: pathology and pathogenesis (abst–2010)  https://www.ncbi.nlm.nih.gov/pubmed/20078219
The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin
secretion and pancreatic β-cell function (abst–2010)  http://www.ncbi.nlm.nih.gov/pubmed/21114601
Effects of chronic nicotine on food intake and anxiety-like behaviour in CB(1) knockout
mice (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20189358
A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans (full–2011) http://joe.endocrinology-journals.org/content/211/2/177.long
Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161308/
Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082575/?tool=pubmed
top
Hepatic n-3 Polyunsaturated Fatty Acid Depletion Promotes Steatosis and Insulin Resistance in Mice: Genomic Analysis of Cellular Targets (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154437/
Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome (full–2011) http://ajpendo.physiology.org/content/300/4/E681.long
Variants at the endocannabinoid receptor CB1 gene (CNR1) and insulin sensitivity, type 2 diabetes, and coronary heart disease (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686489/
Altered endocannabinoid signalling after a high-fat diet in Apoe(-/-) mice: relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance (full–2011) http://link.springer.com/article/10.1007/s00125-011-2274-6/fulltext.html
The association of the rs1049353 polymorphism of the CNR1 gene with hypo-adiponectinemia (full–2011) http://www.rjme.ro/RJME/resources/files/520311791795.pdf
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085542/
GPR119 Regulates Murine Glucose Homeostasis Through Incretin Receptor-Dependent and Independent Mechanisms (full–2011) http://endo.endojournals.org/content/152/2/374.full?sid=c7413b30-1046-4f9c-b028-c46f78f293d9
Central Endocannabinoid Signaling Regulates Hepatic Glucose Production and Systemic Lipolysis (full–2011) http://diabetes.diabetesjournals.org/content/60/4/1055.full
Cannabinoids Inhibit Insulin Receptor Signaling in Pancreatic β-Cells (full–2011) http://diabetes.diabetesjournals.org/content/60/4/1198.full
TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both post-prandial and fasting hyperglycemia in type 2 diabetic rats (full–2011) http://jpet.aspetjournals.org/content/339/1/228.long
Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21340622
Expression of the cannabinoid system in muscle: effects of a high fat diet and CB1 receptor blockade (full–2011) http://www.biochemj.org/content/433/1/175
Role for cannabinoid receptors in human proximal tubular hypertrophy (full–2011) http://content.karger.com/produktedb/produkte.asp?DOI=000323997&typ=pdf
Cannabinoids inhibit insulin receptor signaling in pancreatic β-cells (full–2011)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064093/
Cannabinoid receptor agonists and antagonists stimulate insulin secretion from isolated human islets of Langerhans (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21564460/abstract/Cannabinoid_receptor_agonists_and_antagonists_stimulate_insulin_secretion_from_isolated_human_islets_of_Langerhans_
top
Endocannabinoid signaling and energy metabolism: a target for dietary intervention (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21470818
Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21484568/abstract/Cannabinoids_and_Endocannabinoids_in_Metabolic_Disorders_with_Focus_on_Diabetes_
Win 55,212-2 reduces cardiac ischaemia-reperfusion injury in zucker diabetic fatty rats: role of cb2 receptors and cardiac inos/enos expression (abst–2011)  http://www.ncbi.nlm.nih.gov/pubmed/21309057
Cannabidiol Dampens Streptozotocin-Induced Retinal Inflammation by Targeting of Microglial Activation (abst-2011) http://www.abstractsonline.com/plan/ViewAbstract.aspx?sKey=94b35de1-74b2-4d46-b062-7c104b5df681&cKey=eca34a2d-da44-4938-b0fa-3a6e652a1756
Functional and Structural Protection by N-Acylethanolamines in Diabetic Retinopathy (abst-2011) http://iovs.arvojournals.org/article.aspx?articleid=2356082&resultClick=1
G1359A polymorphism in the cannabinoid receptor-1 gene is associated with coronary  artery disease in the Chinese Han population (abst–2011)  http://www.ncbi.nlm.nih.gov/pubmed/22029183
The role of the endocannabinoid system in islet biology (abst–2011)  http://www.ncbi.nlm.nih.gov/pubmed/21311323
The CB-1 Receptor Antagonist Rimonabant Modulates the Interaction Between  Adipocytes and Pancreatic Beta-Cells in Vitro (abst–2011) https://www.thieme-connect.com/ejournals/abstract/10.1055/s-0030-1261963
Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289985/
The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119 (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423238/
The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity (full–2012) http://diabetes.diabetesjournals.org/content/61/2/281.long
Endocannabinoids measurement in human saliva as potential biomarker of obesity (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409167/?tool=pubmed
Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500919/
Type 2 Diabetes Associated Changes in the Plasma Non-Esterified Fatty Acids, Oxylipins and Endocannabinoids (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493609/
Excess of the endocannabinoid anandamide during lactation induces overweight, fat accumulation and insulin resistance in adult mice (full–2012) http://www.dmsjournal.com/content/4/1/35
Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant (full–2012) http://www.nutritionj.com/content/11/1/50
Does rimonabant independently affect free fatty acid and glucose metabolism? (full–2012) http://www.ncbi.nlm.nih.gov/pubmed/22170727
Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372498/
top
Antihyperglycemic and hypolipidemic effects of α, β-amyrin, a triterpenoid mixture from Protium heptaphyllum in mice (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484111/
The Novel Reversible Fatty Acid Amide Hydrolase Inhibitor ST4070 Increases Endocannabinoid Brain Levels and Counteracts Neuropathic Pain in Different Animal Models (full–2012) http://jpet.aspetjournals.org/content/342/1/188.full.pdf+html
The Endocannabinoid System: Plant-Derived Cannabinoids in Diabetes and Diabetic Complications (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349875/
Fatty acid amide hydrolase ablation promotes ectopic lipid storage and insulin resistance due to centrally mediated hypothyroidism (full-2012) http://www.pnas.org/content/109/37/14966.long
Stimulating beta cell replication and improving islet graft function by GPR119 agonists (full–2012) http://onlinelibrary.wiley.com/doi/10.1111/j.1432-2277.2011.01332.x/full
Islet protection and amelioration of diabetes type 2 in Psammomys obesus by treatment with cannabidiol (link to PDF-2012) http://www.scirp.org/searchResult/Index.aspx?searchCode=Islet+protection+and+amelioration+of+diabetes+type+2+in+Psammomys+obesus+by+treatment+with+cannabidiol
Gut microbiota and the development of obesity (full–2012) http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112012000500007&lng=en&nrm=iso&tlng=en
GPR119 as a fat sensor (full–2012) http://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147%2812%2900054-5
Type 2 Diabetes Associated Changes in the Plasma Non-Esterified Fatty Acids, Oxylipins and Endocannabinoids (full–2012) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0048852
Expression and function of monoacylglycerol lipase in mouse β-cells and human islets of
Langerhans (full–2012) http://www.karger.com/Article/Pdf/339069
Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22609797
Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22268426
Overexpression of cannabinoid CB2 receptor in the brain induces hyperglycaemia and a lean phenotype in adult mice (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22487302
Induction of Glucose Intolerance by Acute Administration of Rimonabant (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22678147
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22374408
G1359A polymorphism in the cannabinoid receptor-1 gene is associated with the presence of coronary artery disease in patients with type 2 diabetes (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22138970
top
A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22669289
Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent (abst–2012)  http://www.ncbi.nlm.nih.gov/pubmed/22490067
An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22921260
The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22943701
Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22743603
Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin-diabetic rats (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22959964
New vistas for treatment of obesity and diabetes? Endocannabinoid signalling and metabolism in the modulation of energy balance (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22674489
NEUROPROTECTIVE EFFECTS OF CANNABIS SATIVA ALCOHOLIC EXTRACT AGAINST SPINAL ALPHA MOTONEURONS DEGENERATION IN MALE TYPE II DIABETIC RATS (abst–2012) http://en.journals.sid.ir/ViewPaper.aspx?ID=278407
Circulating anandamide and blood pressure in patients with obstructive sleep apnea  (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23032139
Fatty acid flux and oxidation are increased by rimonabant in obese women (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22445512
Induction of Glucose Intolerance by Acute Administration of Rimonabant (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22678147
The impact of marijuana use on glucose, insulin, and insulin resistance among US adults (full–2013) http://www.amjmed.com/article/S0002-9343%2813%2900200-3/fulltext
Developmental Role for Endocannabinoid Signaling in Regulating Glucose Metabolism and Growth (full–2013) http://diabetes.diabetesjournals.org/content/62/7/2359.full?sid=2f5bda2b-a9c7-432a-9588-80c99189164d
Chronic activation of cannabinoid receptors in vitro does not compromise mouse islet function (full–2013) http://www.clinsci.org/cs/124/0467/1240467.pdf
Influence of G1359A polimorphysm of the cannabinoid receptor gene (CNR1) on insulin resistance and adipokines in patients with non alcoholic fatty liver disease (full–2013) http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112012000500039&lng=en&nrm=iso&tlng=en
The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671751/
Modulating the endocannabinoid system in human health and disease: successes and failures (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/febs.12260/pdf
top
Reduced Food Intake is the Major Contributor to the Protective Effect of Rimonabant on Islet in Established Obesity-Associated Type 2 Diabetes (full–2013) http://www.eymj.org/DOIx.php?id=10.3349/ymj.2013.54.5.1127
Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese post-menopausal women. A MONET group study (full-2013) http://onlinelibrary.wiley.com/doi/10.1002/oby.20498/full
Insulin induces long-term depression of VTA dopamine neurons via endocannabinoids (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072656/
Is the cardiovascular system a therapeutic target for cannabidiol? (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2012.04351.x/full
The serine hydrolase ABHD6 Is a critical regulator of the metabolic syndrome (full–2013) http://www.cell.com/cell-reports/fulltext/S2211-1247%2813%2900507-X
Cannabinoid Receptor 2 Expression in Human Proximal Tubule Cells is Regulated by Albumin Independent of ERK1/2 Signaling (full-2013) http://www.karger.com/Article/Pdf/354529
A potential role for GPR55 in gastrointestinal functions (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660623/
A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1 (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794927/
Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554318/
Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600727/
Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes (full-2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920793/
Therapeutic Opportunities through the Modulation of Endocannabinoid Transport (full-2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255948/
TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791995/
Polymorphism rs3123554 in CNR2 reveals gender-specific effects on body weight and affects loss of body weight and cerebral insulin action (full-2013) http://onlinelibrary.wiley.com/doi/10.1002/oby.20573/full
Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice (full-2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949647/
Common polymorphism in the cannabinoid type 1 receptor gene (CNR1) is associated with microvascular complications in type 2 diabetes (full–2013) http://www.jdcjournal.com/article/S1056-8727%2813%2900199-2/fulltext
Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839776/
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies (full–2013) http://www.karger.com/Article/FullText/350094
Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of  diabetes and improves beta cell preservation and function in male ZDF rats (full–2013) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668190/
Medicinal Cannabis and Painful Sensory Neuropathy (editorial–2013) http://journalofethics.ama-assn.org/2013/05/oped1-1305.html
top
Effects of C358A polymorphism of the endocannabinoid degrading enzyme fatty acid  amide hydrolase (FAAH) on weight loss, adipocytokines levels, and insulin resistance
after a high polyunsaturated fat diet in obese patients (1st page–2013)  https://link.springer.com/article/10.1007/BF03346760
The complex effects of cannabinoids on insulin secretion from rat isolated islets of Langerhans (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23499687
Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23620336
Synergetic Insulin Sensitizing Effect of Rimonabant and BGP-15 in Zucker-Obes Rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23640247
Activation of type 2 cannabinoid receptors (CB2R) promotes fatty acid oxidation through the SIRT1/PGC-1α pathway (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23747418
Activation of spinal cannabinoid cb2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23892011
Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24120371
Biochemical and immunohistochemical changes in delta-9-tetrahydrocannabinol-treated type 2 diabetic rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23845579
Long-term supplementation of honokiol and magnolol ameliorates body fat accumulation, insulin resistance, and adipose inflammation in high-fat fed mice (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23901038
Islet cannabinoid receptors: cellular distribution and biological function (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24005231
Role of Genetic Variation in the Cannabinoid Receptor Gene (CNR1) (G1359A
Polymorphism) on Weight Loss and Cardiovascular Risk Factors After Liraglutide Treatment in Obese Patients With Diabetes Mellitus Type 2 (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24322329
Fasiglifam as a new potential treatment option for patients with type 2 diabetes (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24195772
Docosahexaenoyl ethanolamide improves glucose uptake and alters endocannabinoid system gene expression in proliferating and differentiating C2C12 myoblasts (full–2014) http://journal.frontiersin.org/Journal/10.3389/fphys.2014.00100/full
A novel GPR40 agonist, CNX-011-67, suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161845/
Effect of intermittent cold exposure on brown fat activation, obesity, and energy homeostasis in mice (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895006/
Vascular targets for cannabinoids: animal and human studies (full–2014) http://onlinelibrary.wiley.com/doi/10.1111/bph.12560/full
top
The effects of obesity, diabetes and metabolic syndrome on the hydrolytic enzymes of the endocannabinoid system in animal and human adipocytes (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995979/
Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839256/
A new face of endocannabinoids in pharmacotherapy. Part II. Role of endocannabinoids in inflammation-derived cardiovascular diseases (full–2014) http://www.jpp.krakow.pl/journal/archive/04_14/pdf/183_04_14_article.pdf
Molecular matchmaking between the popular weight-loss herb Hoodia gordonii and GPR119, a potential drug target for metabolic disorder (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210048/
The G-Protein-Coupled Long-Chain Fatty Acid Receptor GPR40 and Glucose Metabolism (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176464/
Selected terpenoids from medicinal plants modulate endoplasmic reticulum stress in metabolic disorders (full–2014) http://onlinelibrary.wiley.com/doi/10.1111/jphp.12267/full
Glucose concentration in culture medium affects mRNA expression of TRPV1 and CB1 receptors and changes capsaicin toxicity in PC12 cells (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322151/
Optimization of GPR40 Agonists for Type 2 Diabetes (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027784/
Mitochondria: A Possible Nexus for the Regulation of Energy Homeostasis by the Endocannabinoid System? (full–2014) http://ajpendo.physiology.org/content/ajpendo/307/1/E1.full.pdf
Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy (full–2014) http://www.pnas.org/content/111/50/E5420.full?sid=66cd362f-ac53-47ba-920e-b7dae50940a2
Acute Activation of Cannabinoid Receptors by Anandamide Reduces Gastro-Intestinal Motility and Improves Postprandial Glycemia in Mice (full–2014) http://diabetes.diabetesjournals.org/content/64/3/808.long
Cannabidiol improves vasorelaxation in Zucker Diabetic fatty rats through cyclo-oxygenase activation (full–2014) http://jpet.aspetjournals.org/content/351/2/457.long
Cannabis use in relation to obesity and insulin resistance in the inuit population (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/oby.20973/full
α/β-Hydrolase Domain-6-Accessible Monoacylglycerol Controls Glucose-Stimulated  Insulin Secretion (full–2014) http://www.cell.com/cell-metabolism/fulltext/S1550-4131(14)00166-1
Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in  subjects with normal or varying degrees of impaired renal function (full–2014)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269813/
CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion  and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients (full–2014) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994293/
Activation of GPR40 attenuates chronic inflammation induced impact on pancreatic β-
cells health and function (full–2014)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083038/
Molecular Mechanisms of Diabetic Retinopathy, General Preventive Strategies, and Novel Therapeutic Targets (link to PDF–2014)  http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.725.3257&rank=68&q=cannabinoid&osm=&ossid=
A Role for Trans-caryophyllene in the Moderation of Insulin Secretion (abst–2014)  http://www.ncbi.nlm.nih.gov/pubmed/24486541
Glucose metabolism: Focus on gut microbiota, the endocannabinoid system and beyond  (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24631413
Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24827776
top
GPR55: From orphan to metabolic regulator? (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24972076
Physiology and therapeutics of the free fatty acid receptor GPR40 (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24373235
G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24234912
Selected CNR1 polymorphisms and hyperandrogenemia as well as fat mass and fat distribution in women with polycystic ovary syndrome (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25093427
Oxidative stress and cannabinoid receptor expression in type-2 diabetic rat pancreas following treatment with Δ9-THC (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25187240
Potential applications of marijuana and cannabinoids in medicine (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25518584
Elevated CB1 and GPR55 receptor expression in proximal tubule cells and whole kidney exposed to diabetic conditions (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25545857
Role of orphan G protein-coupled receptor 55 in diabetic gastroparesis in mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24964851
The antidiabetic and hepatoprotective effects of magnolol on diabetic rats induced by high-fat diet and streptozotocin (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24974464
Gastrointestinal hormonal responses on GPR119 activation in lean and diseased rodent models of type 2 diabetes (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24451185
Host Neuro- Immuno-Endocrine Responses In Periodontal Disease (abst–2014)  http://www.ncbi.nlm.nih.gov/pubmed/24588827
Increased Plasma Levels of FABP4 and PTEN Is Associated with More Severe Insulin Resistance in Women with Gestational Diabetes Mellitus (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329941/
Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315049/
Changes in Plasma Levels of N-Arachidonoyl Ethanolamine and NPalmitoylethanolamine following Bariatric Surgery in Morbidly Obese Females with Impaired Glucose Homeostasis (full–2015) http://www.ncbi.nlm.nih.gov/pubmed/25874237
Fat Diet-Induced Insulin Resistance Does Not Increase Plasma Anandamide Levels or Potentiate Anandamide Insulinotropic Effect in Isolated Canine Islets (full–2015) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0123558
Atypical diabetic ketoacidosis: case report (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342127/
Role of the endocannabinoid system in obesity induced by neuropeptide Y over-expression in noradrenergic neurons (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423197/
top
Diacylglycerol lipase α knockout mice demonstrate metabolic and behavioral phenotypes similar to those of cannabinoid receptor 1 knockout mice (full–2015) http://journal.frontiersin.org/article/10.3389/fendo.2015.00086/full
Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation (full–2015) http://cardiovascres.oxfordjournals.org/content/early/2015/06/30/cvr.cvv179.long
Cannabis – the Israeli perspective (full–2015) http://www.degruyter.com/view/j/jbcpp.ahead-of-print/jbcpp-2015-0091/jbcpp-2015-0091.xml
Circulating Endocannabinoids and the Polymorphism 385C>A in Fatty Acid Amide Hydrolase (FAAH) Gene May Identify the Obesity Phenotype Related to Cardiometabolic Risk: A Study Conducted in a Brazilian Population of Complex Interethnic Admixture (full–2015) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0142728
Cannabinoid CB1 receptors and mTORC1 signalling pathway interact to modulate glucose homeostasis (full–2015) http://dmm.biologists.org/content/9/1/51.long
Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH) (full–2015) http://cid.oxfordjournals.org/content/61/1/40.long
Dietary DHA reduced downstream endocannabinoid and inflammatory gene expression, epididymal fat mass, and improved aspects of glucose use in muscle in C57BL/6J mice (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722239/
Renal effects of chronic pharmacological manipulation of CB2 receptors in rats with dietinduced obesity (full–2015) http://onlinelibrary.wiley.com/enhanced/doi/10.1111/bph.13056
Alterations in the Medullary Endocannabinoid System Contribute to Age-related Impairment of Baroreflex Sensitivity (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424182/
Cannabis Smoking and Diabetes Mellitus: Results from Meta-analysis with Eight Independent Replication Samples (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801109/
Role of the Endocannabinoid System in Diabetes and Diabetic Complications (full–2015) http://onlinelibrary.wiley.com/doi/10.1111/bph.13226/full
Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5152762/
Endocannabinoid system activation may be associated with insulin resistance in women with polycystic ovary syndrome (full–2015) http://www.fertstert.org/article/S0015-0282(15)00232-0/fulltext
CB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptors (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609878/
Intake of farmed Atlantic salmon fed soybean oil increases hepatic levels of arachidonic acid-derived oxylipins and ceramides in mice (full–2015) http://www.jnutbio.com/article/S0955-2863(15)00021-2/fulltext
Marijuana use and risk of prediabetes and diabetes by middle adulthood: the Coronary Artery Risk Development in Young Adults (CARDIA) study (link to PDF-2015) http://link.springer.com/article/10.1007/s00125-015-3740-3
Adipose tissue NAPE-PLD controls fat mass development by altering the browning  process and gut microbiota (full–2015)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382707/
The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases (link to PDF–2015) http://www.degruyter.com/view/j/jbcpp.ahead-of-print/jbcpp-2015-0055/jbcpp-2015-0055.xml
Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in
Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a
randomized, double-blind, placebo-controlled, phase III trial (full–2015)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676912/
N-Oleoyl glycine, a lipoamino acid, stimulates adipogenesis associated with activation of
CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte (abst–2015)  http://www.sciencedirect.com/science/article/pii/S0006291X15305635
GPR40 agonists for the treatment of type 2 diabetes: life after “TAKing” a hit (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25604916
Direct activation of the proposed anti-diabetic receptor, GPR119 in cardiomyoblasts decreases markers of muscle metabolic activity (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25578601
Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy (abst–2015)
http://www.ncbi.nlm.nih.gov/pubmed/25712641
Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25672659
Major urinary protein 1 interacts with cannabinoid receptor type 1 in fatty acid-induced hepatic insulin resistance in a mouse hepatocyte model (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25843798
top
Cannabinoid functions in the amygdala contribute to conditioned fear memory in streptozotocin-induced diabetic mice: interaction with glutamatergic functions (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25929688
Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids? (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26363623
New insights on the role of the endocannabinoid system in the regulation of energy balance (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26374449
Endocannabinoids and Metabolic Disorders (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26408168
Endocannabinoids and the Cardiovascular System in Health and Disease (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26408169
Deletion of G-protein coupled receptor 55 promotes obesity by reducing physical activity (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26447738
Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26646377
Endocannabinoids – at the crossroads between the gut microbiota and host metabolism  (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26678807
Blockade of Cannabinoid 1 Receptor Improves GLP-1R Mediated Insulin Secretion in Mice (abst–2015) http://www.sciencedirect.com/science/article/pii/S0303720715301714
G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26739335
GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges (abst–2015) http://www.eurekaselect.com/137697/article
Lipid signaling in adipose tissue: Connecting inflammation & metabolism (abst–2015) http://www.sciencedirect.com/science/article/pii/S1388198114002091
The Endocannabinoid System: Pivotal Orchestrator of Obesity and Metabolic Disease  (abst–2015) http://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760(15)00140-X
Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25273317
Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease (full–2016) http://www.hindawi.com/journals/np/2016/8373020/
Cannabinoids Regulate Bcl-2 and Cyclin D2 Expression in Pancreatic β Cells (full– 2016) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0150981
New insights into the yin and yang of the endocannabinoid system in health and disease (full–2016) http://onlinelibrary.wiley.com/doi/10.1111/bph.13451/full
Mechanisms underlying glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854499/
Impaired Excitatory Neurotransmission in the Urinary Bladder from the Obese Zucker Rat: Role of Cannabinoid Receptors (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902197/
Metabolic Syndrome Among Marijuana Users in the United States: An Analysis of National Health and Nutrition Examination Survey Data (full–2016) http://www.amjmed.com/article/S0002-9343(15)01024-4/fulltext
Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes (abst–2016) http://link.springer.com/article/10.1007/s12192-015-0653-5
CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26757949
Prolonged activation of human islet cannabinoid receptors in vitro induces adaptation but not dysfunction (full–2016) http://www.sciencedirect.com/science/article/pii/S2214647416300137
The effect of spinally administered WIN 55,212-2, a cannabinoid agonist, on thermal pain sensitivity in diabetic rats (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887712/
Endocannabinoids in Feeding Behavior and Energy Homeostasis (full–2016) http://themedicalbiochemistrypage.org/endocannabinoids.php
Human CB1 Receptor Isoforms, present in Hepatocytes and β-cells, are Involved in Regulating Metabolism (full–2016) http://www.nature.com/articles/srep33302
Cannabis  Use as Risk or Protection for Type 2 Diabetes: A Longitudinal Study of 18 000  Swedish Men and Women (full–2016)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098083/
Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance (full–2016) http://link.springer.com/article/10.1007%2Fs12020-016-1172-6
Cannabinoid 2 Receptor Agonist Improves Systemic Sensitivity to Insulin in High-Fat Diet/Streptozotocin-Induced Diabetic Mice (full–2016) https://www.karger.com/Article/FullText/453171
α/β-Hydrolase Domain 6 in the Ventromedial Hypothalamus Controls Energy Metabolism Flexibility (full–2016) http://www.cell.com/cell-reports/fulltext/S2211-1247(16)31373-0
Endocannabinoid regulation of β-cell functions: Implications for glycemic control and diabetes (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045244/
Early Low Fat Diet Enriched with Linolenic Acid Reduces Liver Endocannabinoid Tone and Improves Late Glycemic Control After a High Fat Diet Challenge in Mice (full–2016) http://diabetes.diabetesjournals.org/content/65/7/1824.long
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid
Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo Controlled, Parallel Group Pilot Study (full–2016)  http://care.diabetesjournals.org/content/39/10/1777.long
Cannabinoid receptors and TRPA1 on neuroprotection in a model of retinal ischemia  (full–2016) http://www.sciencedirect.com/science/article/pii/S0014483516304791
Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model  (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813387/
Circulating Endocannabinoids and Insulin Resistance in Patients with Obstructive Sleep
Apnea (full–2016) http://www.hindawi.com/journals/bmri/2016/9782031/
Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats  Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas (full–2016)  http://jpet.aspetjournals.org/content/357/1/217.long
Effects of activation of endocannabinoid system on myocardial metabolism (click “ICI” for download–2016) http://www.ncbi.nlm.nih.gov/pubmed/27333924
G protein-coupled receptor 18: A potential role for endocannabinoid signalling in metabolic dysfunction (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26337420
Impaired cued and spatial learning performance and altered cannabinoid CB1 receptor functionality in the substantia nigra in a rat model of diabetic neuropathy (abst–2016) http://www.sciencedirect.com/science/article/pii/S0166432816300249
β-Caryophyllene, a natural sesquiterpene lactone attenuates hyperglycemia mediated oxidative and inflammatory stress in experimental diabetic rats (abst–2016) http://www.sciencedirect.com/science/article/pii/S000927971530154X
Cannabinoid receptor type 1 mediates high-fat diet-induced insulin resistance by increasing forkhead box O1 activity in a mouse model of obesity (abst–2016) http://www.spandidos-publications.com/10.3892/ijmm.2016.2475
Cannabinoids and autoimmune diseases: A systematic review (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26876387
Role of cannabinoid receptors in renal diseases (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26968477
Endovanilloid control of pain modulation by the rostroventromedial medulla in an animal model of diabetic neuropathy (abst–2016) http://www.sciencedirect.com/science/article/pii/S002839081630079X
The role of carbon monoxide on the anti-nociceptive effects and expression of cannabinoid 2 receptors during painful diabetic neuropathy in mice (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27020787
Hierarchical glucocorticoid-endocannabinoid interplay regulates the activation of the nucleus accumbens by insulin (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27208730
Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27178047
Anandamide reverses depressive-like behavior, neurochemical abnormalities and oxidative-stress parameters in streptozotocin-diabetic rats: Role of CB1 receptors (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27544303
GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27561953
Marijuana Use and Type 2 Diabetes Mellitus: a Review (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27747490
Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27767974
Cannabinoid receptors and TRPA1 on neuroprotection in a model of retinal ischemia (abst–2016) http://www.sciencedirect.com/science/article/pii/S0014483516304791
Developmental Role of Macrophage Cannabinoid-1 Receptor Signaling in Type-2 Diabetes (abst–2017) http://diabetes.diabetesjournals.org/content/early/2017/01/11/db16-1199.long
top
GPR55: a new promising target for metabolism? (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28196832
Overactivation of the endocannabinoid system alters the anti-lipolytic action of insulin in mouse adipose tissue (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28325733
Metabolic Syndrome Induced Bladder Cannabinoid Receptor Changes in the Fructose Fed Rats (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28386998
Dual therapy targeting the endocannabinoid system prevents experimental diabetic
nephropathy (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28387811
Diabetes Management by Probiotics: Current Knowledge and Future Pespective (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28436760
GPR55 and the regulation of glucose homeostasis (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28457969
High-Throughput Screening and Bioinformatic Analysis to Ascertain Compounds that
Prevent Saturated Fatty Acid-Induced β-Cell Apoptosis (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0006295217302575?via%3Dihub
CB-1R and GLP-1R gene expressions and oxidative stress in the liver of diabetic rats
treated with sitagliptin (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28599244
A TRPV1‐to‐secretagogin regulatory axis controls pancreatic β‐cell survival by  modulating protein turnover (abst–2017)  http://emboj.embopress.org/content/early/2017/06/19/embj.201695347.long
Incretin Secretion in Humans is under the Influence of Cannabinoid Receptors (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28655715
Neuroprotection by (endo)cannabinoids in glaucoma and retinal neurodegenerative
diseases (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28738764
Polymorphism rs3123554 in the cannabinoid receptor gene type 2 (CNR2) reveals effects  on body weight and insulin resistance in obese subjects (abst–2017)  http://www.sciencedirect.com/science/article/pii/S2530016417301799?via%3Dihub
The role of cannabinoid receptors in renal diseases (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28901271
Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and
Associated Diseases (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28913816
In vitro and in vivo pharmacological characterization of ASP8477: A novel highly
selective fatty acid amide hydrolase inhibitor (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/29017758
Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the  Treatment of Diabetic Nephropathy (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/29030466
Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular
dysfunction in a mouse model of diabetic nephropathy (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/29106063
The Inhibitory Effects of Cobalt Protoporphyrin IX and Cannabinoid 2 Receptor Agonists in Type 2 Diabetic Mice (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/29143802
LH-21 and Abn-CBD improve β-cell function in isolated human and mouse islets through GPR55-dependent and -independent signalling (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/29205751
Role of Endocannabinoids on Sweet Taste Perception, Food Preference, and Obesity related Disorders (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/29293950
Caloric restriction lowers endocannabinoid tonus and improves cardiac function in type 2 diabetes (full–2018) https://www.nature.com/articles/s41387-017-0016-7
Increased Levels of Circulating Fatty Acids Are Associated with Protective Effects against Future Cardiovascular Events in Nondiabetics (abst–2018)  http://pubs.acs.org/doi/10.1021/acs.jproteome.7b00671
Omega-3 fatty acids and adipose tissue biology (abst–2018)  https://www.sciencedirect.com/science/article/pii/S0098299717301620?via%3Dihub
Cannabinoid Receptors in Diabetic Kidney Disease (abst–2018)  https://link.springer.com/article/10.1007%2Fs11892-018-0975-7


DIARRHEA
Small intestinal cannabinoid receptor changes following a single colonic insult with oil of mustard in mice (full–2010) http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00132/full
Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in Patients with Non-Constipated Irritable Bowel Syndrome (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202649/
US Patent 7884133 B2 Cannabidiol derivatives such as 3-(2,6-dihydroxy-4- pentylphenyl)-4-prop-1-en-2-ylcyclohexene-1-carboxylic acid, used as as analgesics, antiinflammatory and antidiarrheal agents (full–2011) https://www.google.com/patents/US7884133?dq=patent+7884133&hl=en&sa=X&ei=Ujb0U_6EEIW5ogSl84LYDg&ved=0CB4Q6AEwAA Cannabis use amongst patients with inflammatory bowel disease (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21795981
Medical cannabis: the opportunity versus the temptation (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/22352284
Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775711/
Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted
from Cannabis sativa, on inflammation-induced hypermotility in mice (full–2012)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417459/
Irritable bowel syndrome: a dysfunction of the endocannabinoid system? (full–2012)
http://www.gastrojournal.org/article/S0016-5085%2811%2901710-0/fulltext
Pro-resolution, protective and anti-nociceptive effects of a cannabis extract in the rat gastrointestinal tract (full–2013) http://www.jpp.krakow.pl/journal/archive/04_13/pdf/167_04_13_article.pdf
Cannabinoid Receptor 1 Gene and Irritable Bowel Syndrome: Phenotype and Quantitative Traits (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602676/
Effect of high fat-diet and obesity on gastrointestinal motility (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890396/
Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study (full–2013) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085073
Role of endogenous cannabinoid system in the gut (full-2013) http://www.actaps.com.cn/qikan/manage/wenzhang/2013-4-12.pdf
Cannabis Finds Its Way into Treatment of Crohn’s Disease (full–2013)  http://www.karger.com/Article/Pdf/356512
Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides (full–2014) http://onlinelibrary.wiley.com/doi/10.1111/nmo.12272/full
Cannabis for inflammatory bowel disease (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24969296
Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease (abst–2014) https://www.ncbi.nlm.nih.gov/pubmed/24407485
In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on
gastrointestinal motor function in the rat (full–2015)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918633/
The long-term functional consequences of acute infectious diarrhea (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26628101
The role of cannabinoids in regulation of nausea and vomiting, and visceral pain (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25715910
MEDICAL CANNABIS (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27215115
Role of cannabinoids in gastrointestinal mucosal defense and inflammation (abst–2016) http://www.eurekaselect.com/140045/article
May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27686064
Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/26809974
Cannabinoids for treating inflammatory bowel diseases: where are we and where do we  go? (full–2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388177/
Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process
induced by Clostridium difficile toxin A in Caco-2 cells (full–2017)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721977/
Modulation of the endocannabinoid system by the fatty acid amide hydrolase,
monoacylglycerol and diacylglycerol lipase inhibitors as an attractive target for secretory diarrhoea therapy (click “Full Text Link” for download-2017)  https://www.ncbi.nlm.nih.gov/pubmed/29151076
Role of cannabis in digestive disorders (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/27792038
Cannabinoids as gastrointestinal anti-inflammatory drugs (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28239924
Targeting fatty acid amide hydrolase and transient receptor potential vanilloid-1
simultaneously to modulate colonic motility and visceral sensation in the mouse: A
pharmacological intervention with N-arachidonoyl-serotonin (AA-5-HT) (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28695708


DOWN SYNDROME +
Gadolinium-HU-308-incorporated micelles (full–2011) http://www.ncbi.nlm.nih.gov/books/NBK54067/pdf/CB2R-Gd-Micelles.pdf
Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a (full-2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953590/
Monoacylglycerol Lipase Inhibitor JZL184 Improves Behavior and Neural Properties in Ts65Dn Mice, a Model of Down Syndrome (full-2014) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0114521
top


DRIVING AND CANNABIS
Sex Differences in the Effects of Marijuana on Simulated Driving Performance (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033009/?tool=pmcentrez
The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand (abst-2010) http://www.unboundmedicine.com/medline/ebm/record/20380913/abstract/The_effects_of_cannabis_and_alcohol_on_simulated_arterial_driving:_Influences_of_driving_experience_and_task_demand_
Does cannabis use increase the risk of death? Systematic review of epidemiological  evidence on adverse effects of cannabis use (abst–2010)  http://www.ncbi.nlm.nih.gov/pubmed/20565525
Medical Marijuana Laws, Traffic Fatalities, and Alcohol Consumption (full–2011) http://ftp.iza.org/dp6112.pdf
The prevalence of cannabis-involved driving in California (full–2011) http://www.sciencedirect.com/science/article/pii/S0376871611004741
Alcohol, psychoactive drugs and fatal road traffic accidents in Norway: a case-control study (abst-2011) http://www.unboundmedicine.com/medline/ebm/record/21376919/abstract/Alcohol_psychoactive_drugs_and_fatal_road_traffic_accidents_in_Norway:_a_case_control_study_
Drunk versus drugged: How different are the drivers? (abst–2011)  http://www.ncbi.nlm.nih.gov/pubmed/21925803
Psychomotor Performance, Subjective and Physiological Effects and Whole Blood Δ9-Tetrahydrocannabinol Concentrations in Heavy, Chronic Cannabis Smokers Following Acute Smoked Cannabis (full–2012) http://jat.oxfordjournals.org/content/36/6/405.full
A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid (full-2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456923/
The Therapeutic Potential of Cannabis and Cannabinoids (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442177/
Cannabis and psychomotor performance: A rational review of the evidence and implications for public policy (article-2012) http://www.letfreedomgrow.com/cmu/Armentano-Cannabis-and-psychomotor-performance.pdf
THCVA-A – a new additional marker for illegal cannabis consumption (abst–2012) http://www.sciencedirect.com/science/article/pii/S0379073811001150
Cannabis use: a perspective in relation to the proposed UK drug-driving legislation (full-2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1588/full
Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers’ blood on per se drugged driving laws (full-2013) http://www.clinchem.org/content/59/3/519.full?sid=c00c9727-29e8-493c-83b8-456467e158b9
Current knowledge on cannabinoids in oral fluid (full–2013)  http://onlinelibrary.wiley.com/doi/10.1002/dta.1514/full
Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic  frequent and occasional smokers (full–2013)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823692/
Prevalence of alcohol and other drugs and the concentrations in blood of drivers killed in road traffic crashes in Sweden (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/24265165
THCCOOH concentrations in whole blood: Are they useful in discriminating occasional from heavy smokers? (full-2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1581/full
Comparison between self-report of cannabis use and toxicological detection of THC / THCCOOH in blood and THC in oral fluid in drivers in a roadside survey (full-2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1517/full
Driving Under the Influence of Cannabis: Pitfalls, Validation, and Quality Control of a UPLC-MS/MS Method for the Quantification of Tetrahydrocannabinol in Oral Fluid Collected With StatSure, Quantisal, or Certus Collector (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/23318281
top
Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/23369054
Risk of severe driver injury by driving with psychoactive substances (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/23867258
Police custody following driving under the influence of cannabis: A prospective study (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/23890621
Blood Synthetic Cannabinoid Concentrations in Cases of Suspected Impaired Driving (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/23965292
Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/24129318
Analysis of AM-2201 and metabolites in a drugs and driving case (abst-2013)  http://www.ncbi.nlm.nih.gov/pubmed/24574312
Marijuana Policy in Colorado (full-2014) http://object.cato.org/sites/cato.org/files/pubs/pdf/working-paper-24_2.pdf
Adverse psychosocial outcomes associated with drug use among US high school seniors:
a comparison of alcohol and marijuana (full-2014) http://informahealthcare.com/doi/pdf/10.3109/00952990.2014.943371
Blood levels do not predict behavioral or physiological effects of Δ⁹-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure (full-2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251811/
XLR-11 and UR-144 in Washington State and State of Alaska Driving Cases (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25217547
Detection and Prevalence of Drug Use in Arrested Drivers Using the Dräger Drug Test
5000 and Affiniton DrugWipe Oral Fluid Drug Screening Devices (full–2014)  https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bku050
Cannabis Use and its Effects on Health, Education and Labor Market Success (link to PDF-2014) http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2414469
An examination of the validity of the standardized field sobriety test in detecting drug impairment using data from the drug evaluation and classification program (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24345013
Driving under the influence of synthetic cannabinoids (“Spice”): a case series (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/23636569
The culpability of drivers killed in New Zealand road crashes and their use of alcohol and other drugs (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24636874
Determination of Δ9-tetrahydrocannabinolic acid A (Δ9-THCA-A) in whole blood and plasma by LC-MS/MS and application in authentic samples from drivers suspected of driving under the influence of cannabis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25173986
Cannabinoids determination in oral fluid by SPME-GC/MS and UHPLC-MS/MS and its application on suspected drivers (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25498928
Driving Under the Influence of Synthetic Cannabinoid Receptor Agonist XLR-11 (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25088081
Status Report: Marijuana Legalization in Colorado After One Year of Retail Sales and Two Years of Decriminalization (full–2015) http://www.drugpolicy.org/sites/default/files/Colorado_Marijuana_Legalization_One_Year_Status_Report.pdf
Drug and Alcohol Crash Risk (full–2015) http://kimabim.s3.amazonaws.com/812117-Drug_and_Alcohol_Crash_Risk.pdf
top
Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol (full–2015) http://www.clinchem.org/content/61/6/850.long
Comparing treatment effects of oral THC on simulated and on-the-road driving performance: testing the validity of driving simulator drug research (full–2015) http://link.springer.com/article/10.1007/s00213-015-3927-9/fulltext.html
Medical marijuana’s public health lessons–implications for retail marijuana in Colorado (full–2015) http://www.nejm.org/doi/full/10.1056/NEJMp1500043
Driving Under the Influence of Marijuana Versus Driving and Dying Under the Influence of Marijuana: A Comparison of Blood Concentrations of Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol, 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol and Other Cannabinoids in Arrested Drivers Versus Deceased Drivers (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26378132
Concentrations of AB-CHMINACA and AB-PINACA and Driving Behavior in Suspected Impaired Driving Cases (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26378139
Cannabis conundrum: Evidence of harm?: Opposition to marijuana use is often rooted in arguments about the drug’s harm to children and adults, but the scientific evidence is seldom clear-cut (article–2015) http://onlinelibrary.wiley.com/doi/10.1002/cncy.21516/full
Peaceful feeling, or up in smoke? Medical marijuana in medicolegal context (article–2015) http://www.mdedge.com/currentpsychiatry/article/102099/practice-management/peaceful-feeling-orsmoke-medical-marijuana
Drug-resistant MS spasticity treatment with Sativex® add-on and driving ability (full–2015) http://onlinelibrary.wiley.com/doi/10.1111/ane.12287/full
The Influence of Synthetic Cannabinoid UR-144 on Human Psychomotor Performance -A Case Report Demonstrating Road Traffic Risks (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25794331
Delays in DUI blood testing: Impact on cannabis DUI assessments (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26066003
Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26427296
Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/26653952
Ion mobility spectrometry for detection of Cannabis sativa L. metabolites from exhaled breath (abst-2015) https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0035-1565285
The impact of marijuana decriminalization on California drivers (abst-2015) http://www.drugandalcoholdependence.com/article/S0376-8716%2815%2900108-8/abstract
Restraint use and risky driving behaviors across drug types and drug and alcohol combinations for drivers involved in a fatal motor vehicle collision on U.S. roadways (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819806/
Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues (full–2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00309/full
Effect of Blood Collection Time on Measured Δ9-Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy (abst-2016) http://www.ncbi.nlm.nih.gov/pubmed/26823611
Dose of Reality: The Effect of State Marijuana Legalizations (report–2016) http://www.cato.org/publications/policy-analysis/dose-reality-effect-state-marijuana-legalizations#full
Are We Using the Right Model of Cannabis Tolerance? (letter–2016)  http://www.jsad.com/doi/10.15288/jsad.2016.77.992
The effect of cannabis on regular cannabis consumers’ ability to ride a bicycle (abst-2016) http://www.ncbi.nlm.nih.gov/pubmed/26739323
top
The Changing Drug Culture: Medical and Recreational Marijuana (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26881768

Cannabis effects on driving longitudinal control with and without alcohol (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26889769
The effects of cannabis intoxication on motor vehicle collision revisited and revised (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26878835
Traffic accidentability and risky driving behavior in young people in New Caledonia. Results of study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27259836
A multicenter retrospective survey of poisoning after consumption of products containing novel psychoactive substances from 2013 to 2014 in Japan (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27314752
State Medical Marijuana Laws and the Prevalence of Opioids Detected Among Fatally Injured Drivers (abst–2016) http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2016.303426?journalCode=ajph
Persistent cannabis dependence and alcohol dependence represent risks for midlife economic and social problems: A longitudinal cohort study (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/28008372
US Traffic Fatalities, 1985–2014, and Their Relationship to Medical Marijuana Laws (abst–2016) http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2016.303577
Small Molecule Detection in Saliva Facilitates Portable Tests of Marijuana Abuse (abst–2016) http://pubs.acs.org/doi/abs/10.1021/acs.analchem.6b01688
Illicit Drugs in Oral Fluid: Evaluation of Two Collection Devices (abst–2016)  https://www.ncbi.nlm.nih.gov/pubmed/27681339
Recreational Cannabis — Minimizing the Health Risks from Legalization (full–2017) http://www.nejm.org/doi/full/10.1056/NEJMp1614783
Motor vehicle collisions caused by the ‘super-strength’ synthetic cannabinoids, MAM2201, 5F-PB-22, 5F-AB-PINACA, 5F-AMB and 5F-ADB in Japan experienced from
2012 to 2014 (full–2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486620/
A Guide to the National Academy of Science Report on Cannabis: An Exclusive
Discussion with Panel Members (full–2017)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569624/
Cannabis, alcohol and fatal road accidents (full–2017)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678710/
Self-reported Driving Under the Influence of Alcohol and Cannabis Among Ontario Students: Associations with Graduated Licensing, Risk Taking and Substance Abuse (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28095034
Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28138971
Marijuana and other substance use among male and female underage drinkers who drive after drinking and ride with those who drive after drinking (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28231494
Street racing among the Ontario adult population: Prevalence and association with  collision risk (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0001457517301203
The Relation between Driving Violations and Health Promotion Behaviors among  Under-graduate Students: Self-Report of Road Behavior (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28409675
Increasing Use of Cannabis among Arrested Drivers in Norway (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28448164
THC and CBD in blood samples and seizures in Norway: Does CBD affect THC-induced
impairment in apprehended subjects? (abst–2017)  http://www.fsijournal.org/article/S0379-0738(17)30143-3/fulltext
Crash Fatality Rates After Recreational Marijuana Legalization in Washington and  Colorado (abst–2017) http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2017.303848
Evaluation of Oral Fluid as a Specimen for DUID (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28633318
Driving under the influence of drugs: Perceptions and attitudes of New Zealand drivers  (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28554064
Prevalence and motives for drugged driving among emerging adults presenting to an
emergency department (abst–2017)  https://www.sciencedirect.com/science/article/pii/S0306460317304008?via%3Dihub
Older Adults Driving Under the Influence: Associations With Marijuana Use, Marijuana  Use Disorder, and Risk Perceptions (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/29199501
Visual attention to motion stimuli and its neural correlates in cannabis users (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/29266467
Developing a theoretical foundation to change road user behavior and improve traffic  safety: Driving under the influence of cannabis (DUIC) (abst–2018)  https://www.ncbi.nlm.nih.gov/pubmed/29337600


DRUG TESTING*+
Testing for cannabis in the work-place: a review of the evidence (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20402984
Zinc Reduces the Detection of Cocaine, Methamphetamine, and THC by ELISA Urine Testing (full-2011) We need 8 to 11 mg of zinc daily; over 40 mg/day can cause zinc poisoning http://jat.oxfordjournals.org/content/35/6/333.long
Postmortem redistribution of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OHTHC), and 11-nor-9-carboxy-THC (THCCOOH) (full-2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413259/
Use of high-resolution accurate mass spectrometry to detect reported and previously  unreported cannabinomimetics in “herbal high” products (link to PDF–2011)  http://jat.oxfordjournals.org/content/34/5/252.long
Cannabinoids in postmortem toxicology (link to PDF–2011)  http://jat.oxfordjournals.org/content/35/7/394.long
Immunochemical approach using monoclonal antibody against Δ(9)-
tetrahydrocannabinolic acid (THCA) to discern cannabis plants and to investigate new
drug candidates (link to download–2011) http://www.eurekaselect.com/94339/article
Prolonged excretion half-life of 11-nor-9-carboxy-Δ⁹-THC following cessation in a chronic, heavy marijuana user: implications for liver transplant assessment (1st page–2011) http://www.psychosomaticsjournal.com/article/S0033-3182%2810%2900028-9/abstract
A preliminary investigation on the distribution of cannabinoids in man (abst-2011) http://www.unboundmedicine.com/medline/ebm/record/21570784/abstract/A_preliminary_investigation_on_the_distribution_of_cannabinoids_in_man_
Simultaneous determination of delta-9-tetrahydrocannabinol cannabidiol and cannabinol in edible oil using ultra performance liquid chromatography-tandem mass spectrometry (abst-2011) http://www.unboundmedicine.com/medline/ebm/record/21381415/abstract/%5BSimultaneous_determination_of_delta_9_tetrahydrocannabinol_cannabidiol_and_cannabinol_in_edible_oil_using_ultra_performance_liquid_chromatography_tandem_mass_spectrometry%5D_
Metabolic acidosis, hypoglycemia, and severe myalgias: an attempt to mask urine drug screen results (abst-2011) http://www.ncbi.nlm.nih.gov/pubmed/21467883
Detection of synthetic cannabinoids in herbal incense products. (abst – 2011)
http://www.ncbi.nlm.nih.gov/pubmed/21741374
A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid (full-2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456923/
Cannabis misinterpretation and misadventure in a coroner’s court (full–2012) http://journals.sagepub.com/doi/full/10.1258/msl.2011.011087
Cannabis use: a perspective in relation to the proposed UK drug-driving legislation (full–2013) http://link.springer.com/article/10.1186/s40621-014-0026-z
Cannabis – from cultivar to chemovar (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22362625
top
Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay (abst-2012) http://www.ncbi.nlm.nih.gov/pubmed/22465236
Detecting impairment associated with cannabis with and without alcohol on the Standardized Field Sobriety Tests (abst-2012) http://www.ncbi.nlm.nih.gov/pubmed/22763669
Are cannabis prevalence estimates comparable across countries and regions? A cross-cultural validation using search engine query data (abst-2012)
http://www.ncbi.nlm.nih.gov/pubmed/22809479
Does a positive finding of tetrahydrocannabinol in the blood result from ingestion of Indian frankincense (Boswellia serrata)? (abst-2012) http://www.unboundmedicine.com/medline/citation/22834359/%5BDoes_a_positive_finding_of_tetrahydrocannabinol_in_the_blood_result_from_ingestion_of_Indian_frankincense_%28Boswellia_serrata%29
Manual for use by national drug analysis laboratories Recommended methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials (full–2013) http://www.unodc.org/documents/scientific/STNAR48_Synthetic_Cannabinoids_ENG.pdf
Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration (full-2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758774/
Identification and Structural Elucidation of Four Cannabimimetic Compounds (RCS-4, AM-2201, JWH-203 and JWH-210) in Seized Products (full–2013) http://jat.oxfordjournals.org/content/37/2/56.full.pdf+html
Elevated urine zinc concentration reduces the detection of methamphetamine, cocaine, THC and opiates in urine by EMIT (full–2013) Adults need 8 to 11 mg of zinc daily; over 40 mg/day can cause zinc poisoning http://jat.oxfordjournals.org/content/37/9/665.full Identification of Novel Third-Generation Synthetic Cannabinoids in Products by UltraPerformance Liquid Chromatography and Time-of-Flight Mass Spectrometry (full–2013) https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkt062
Marijuana Poisoning (dogs) (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23796481
Analysis of THCA synthase gene expression in cannabis: A preliminary study by realtime quantitative PCR (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23890639
An in vitro experiment on the interaction of charcoal or wheat bran with 11-nor-9-carboxy-Δ9-tetrahydrocannabinol and its glucuronide (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/24077855
Tricks and Tracks in the Identification and Quantification of Endocannabinoids (abst-2013) http://onlinelibrary.wiley.com/doi/10.1002/9780470015902.a0023407/abstract
Police custody following driving under the influence of cannabis: A prospective study  (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23890621
Synthetic cannabinoid use among patients in residential substance use disorder treatment: Prevalence, motives, and correlates (full-2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161625/
An examination of the validity of the standardized field sobriety test in detecting drug impairment using data from the drug evaluation and classification program (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24345013
top
Metals and organic compounds in the biosynthesis of cannabinoids: a chemometric approach to the analysis of Cannabis sativa samples (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24483128
Workplace drug testing in Italy: Findings about second-stage testing (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24652693
Behaviours of psychotropic substances in indoor and outdoor environments of Rome, Italy (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24705952
Cocaine’s fall and marijuana’s rise: questions and insights based on new estimates of consumption and expenditures in US drug markets (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/25039446
A structure-reactivity relationship driven approach to the identification of a color test protocol for the presumptive indication of synthetic cannabimimetic drugs of abuse (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/25062530
Simultaneous quantification of delta-9-THC, THC-acid A, CBN and CBD in seized drugs using HPLC-DAD (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/25005819
Annual banned-substance review: analytical approaches in human sports drug testing (full-2015) http://onlinelibrary.wiley.com/doi/10.1002/dta.1769/full
A Reliable Method for the Separation and Detection of Synthetic Cannabinoids by Supercritical Fluid Chromatography with Mass Spectrometry, and Its Application to Plant Products (full-2015) https://www.jstage.jst.go.jp/article/cpb/63/10/63_c15-00170/_html
Emerging drugs of abuse: current perspectives on synthetic cannabinoids (full-2015)
https://www.dovepress.com/emerging-drugs-of-abuse-current-perspectives-on-synthetic-cannabinoidspeer-reviewed-fulltext-article-SAR
Method for the Analysis of Cannabinoids and Terpenes in Cannabis (link to PDF–2015) http://tinyurl.com/z6j5xhe
A robust capillary liquid chromatography/tandem mass spectrometry method for quantitation of neuromodulatory endocannabinoids (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/26411510
Seized cannabis seeds cultivated in greenhouse: A chemical study by gas  chromatography–mass spectrometry and chemometric analysis (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/26746824
Determination of 11 Cannabinoids in Biomass and Extracts of Different Varieties of Cannabis Using High-Performance Liquid Chromatography (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/26651563
Population Pharmacokinetic Model of THC Integrates Oral, Intravenous, and Pulmonary Dosing and Characterizes Short- and Long-term Pharmacokinetics (abst–2015) http://link.springer.com/article/10.1007/s40262-014-0195-5
top
Delays in DUI blood testing: Impact on cannabis DUI assessments (abst–2015)  http://www.ncbi.nlm.nih.gov/pubmed/26066003
Lipidomic Analysis of Endocannabinoid Signaling: Targeted Metabolite Identification and Quantification (full–2016) http://www.hindawi.com/journals/np/2016/2426398/ Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27400642
Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27005853
Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method (abst–2016) http://www.sciencedirect.com/science/article/pii/S0731708516302722
Extraction and Simultaneous Quantification of Endocannabinoids and Endocannabinoid Like Lipids in Biological Tissues (abst–2016) http://link.springer.com/protocol/10.1007%2F978-1-4939-3539-0_2
The Application of Voltammetric Analysis of Δ(9) -THC for the Reduction of False Positive Results in the Analysis of Suspected Marijuana Plant Matter (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27364289
Synthetic cannabinoids to avoid urine drug screens: Implications for contingency management and other treatments for drug dependence (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27424166
Use of Embryos Extracted from Individual Cannabis sativa Seeds for Genetic Studies and Forensic Applications (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27404624
Buying drugs on a Darknet market: A better deal? Studying the online illicit drug market through the analysis of digital, physical and chemical data (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27611957
Interpretation of Workplace Tests for Cannabinoids (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27686239
A systematic review of passive exposure to cannabis (abst–2016) http://www.fsijournal.org/article/S0379-0738(16)30493-5/abstract
top
Antibody Fragments for On-Site Testing of Cannabinoids Generated via in Vitro Affinity
Maturation (full–2017) https://www.jstage.jst.go.jp/article/bpb/40/2/40_b16-00669/_html
Cannabis: Exercise performance and sport. A systematic review (full–2017)  http://www.jsams.org/article/S1440-2440(17)30342-0/fulltext
Commercial herbal medicines used as African traditional medicines: Ngoma Herbal
Tonic Immune Booster interferes with a rapid urine drug screening test (full-2017)
https://www.ajol.info/index.php/samj/article/view/161438/151005
Pharmaceutical and biomedical analysis of cannabinoids: A critical review (full–2017) http://www.sciencedirect.com/science/article/pii/S0731708517311895
Work place drug testing of police officers after THC exposure during large volume
cannabis seizures (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0379073817301342
Development of a new extraction technique and HPLC method for the analysis of nonpsychoactive cannabinoids in fibre-type Cannabis sativa L. (hemp) (abst–2017)
http://www.sciencedirect.com/science/article/pii/S0731708517303527
Cross-Reactivity of Pantoprazole with Three Commercial Cannabinoids Immunoassays  in Urine (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28985315
Up in Smoke: Uncovering a Lack of Evidence for Proton Pump Inhibitors as a Source of
Tetrahydrocannibol Immunoassay False Positives (abst–2017)  https://academic.oup.com/painmedicine/advance-article-abstract/doi/10.1093/pm/pnx266/4604941?redirectedFrom=fulltext
Determination of Acid and Neutral Cannabinoids in Extracts of Different Strains of
Cannabis sativa Using GC-FID (abst–2017) https://www.thieme-connect.com/DOI/DOI?10.1055/s-0043-124088
Detection and Quantification of Cannabinoids in Extracts of Cannabis sativa Roots Using
LC-MS/MS (1st page–2018) https://www.thieme-connect.com/DOI/DOI?10.1055/s-0044-100798
Instability and poor recovery of cannabinoids in urine, oral fluid, and hair (abst–2018) https://www.ncbi.nlm.nih.gov/pubmed/29273570
Marijuana-Perinatal and Legal Issues With Use During Pregnancy (abst–2018)  https://www.ncbi.nlm.nih.gov/pubmed/29373417


DRUG TESTING-ATMOSPHERIC
Drugs of abuse in airborne particulates in urban environments (abst–2010)  http://www.unboundmedicine.com/medline/ebm/record/20447692/abstract/Drugs_of_abuse_in_airborne_particulates_in_urban_environments_
Versatile new ion source for the analysis of materials in open air under ambient
conditions (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/15828760
Behaviours of psychotropic substances in indoor and outdoor environments of Rome,
Italy (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24705952
Psychotropic substances in indoor environments (abst–2014)  http://www.sciencedirect.com/science/article/pii/S0160412014001834
Comprehensive monitoring of the occurrence of 22 drugs of abuse and transformation  products in airborne particulate matter in the city of Barcelona (abst–2015)  http://www.sciencedirect.com/science/article/pii/S0048969715302254
Illicit psychotropic substances in the air: The state-of-art (abst–2015)  http://www.sciencedirect.com/science/article/pii/S0048969715305556


DRUG TESTING-BLOOD/PLASMA*+
Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydro-cannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop (full-2010) http://jat.oxfordjournals.org/content/34/4/196.long
Quantitation of Total 11-Nor-9-Carboxy-Delta 9-Tetrahydrocannabinol in Urine and Blood Using Gas Chromatography-Mass Spectrometry (GC-MS) (abst-2010) http://marijuana.researchtoday.net/archive/7/1/2746.htm
Interpretation of blood analysis data found after passive exposure to cannabis abst–2010) http://www.unboundmedicine.com/medline/ebm/record/20506708/abstract/%5BInterpretation_of_blood_analysis_data_found_after_passive_exposure_to_cannabis%5D_
Testing for cannabis in the work-place: a review of the evidence (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20402984
Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users (abst-2010) http://www.ncbi.nlm.nih.gov/pubmed/21116612
Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration (full–2011) http://www.clinchem.org/content/57/1/66.long
Oral Fluid and Plasma Cannabinoid Ratios after Around-the-Clock Controlled Oral [Delta]9-Tetrahydrocannabinol Administration (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836268/
Identification of Recent Cannabis Use:Whole-Blood and Plasma Free and Glucuronidated Cannabinoid Pharmacokinetics Following Controlled Smoked Cannabis Administration (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717336/
Development and validation of a liquid chromatography-tandem mass spectrometry  method for the identification and quantification of JWH-018, JWH-073, JWH-019, and  JWH-250 in human whole blood (full–2011)  http://jat.oxfordjournals.org/content/35/7/386.long
Variability of cannabinoid findings in blood (abst–2011)  http://www.ncbi.nlm.nih.gov/pubmed/21850885
Alcohol, psychoactive drugs and fatal road traffic accidents in Norway: a case-control  study (abst–2011) http://www.sciencedirect.com/science/article/pii/S0001457510004112?via%3Dihub
Psychomotor Performance, Subjective and Physiological Effects and Whole Blood Δ9-Tetrahydrocannabinol Concentrations in Heavy, Chronic Cannabis Smokers Following Acute Smoked Cannabis (full–2012) http://jat.oxfordjournals.org/content/36/6/405.full
top
Detection and disposition of JWH-018 and JWH-073 in mice after exposure to “Magic Gold” smoke (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677765/
Determination of naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in mouse blood and tissue after inhalation exposure to ‘buzz’ smoke by HPLC/MS/MS (abst–2012) http://onlinelibrary.wiley.com/doi/10.1002/bmc.2710/abstract
Detection and quantification of new designer drugs in human blood: part 1 – synthetic cannabinoids (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22593567
Predictive model accuracy in estimating last Δ(9)-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC (abst–2012) http://www.sciencedirect.com/science/article/pii/S0376871612000798
Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction (abst–2012) http://onlinelibrary.wiley.com/doi/10.1002/jms.3020/abstract
Does a positive finding of tetrahydrocannabinol in the blood result from ingestion of Indian frankincense (Boswellia serrata)? (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22834359
Determination of the two major endocannabinoids in human plasma by μ-SPE followed by HPLC-MS/MS (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22847477
Distribution of free and conjugated cannabinoids in human bile samples (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22980143
Dried Blood Spots: Liquid chromatography-mass spectrometry analysis of Δ(9)-tetrahydrocannabinol and its main metabolites (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23228918
THCVA-A – a new additional marker for illegal cannabis consumption (abst–2012) http://www.sciencedirect.com/science/article/pii/S0379073811001150
Cannabis, possible cardiac deaths and the coroner in Ireland (abst–2012)  https://www.ncbi.nlm.nih.gov/pubmed/22231902
In Vitro Stability of Free and Glucuronidated Cannabinoids in Blood and Plasma Following Controlled Smoked Cannabis (full–2013) http://www.clinchem.org/content/59/7/1108.full?sid=c00c9727-29e8-493c-83b8-456467e158b9
Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers’ blood on per se drugged driving laws (full–2013) http://www.clinchem.org/content/59/3/519.full?sid=c00c9727-29e8-493c-83b8-456467e158b9
Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870889/
Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758774/
Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955404/
Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study (full–2013) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085073
Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24129318
THCCOOH concentrations in whole blood: Are they useful in discriminating occasional from heavy smokers? (full–2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1581/full
top
Simultaneous and sensitive LC–MS/MS determination of tetrahydrocannabinol and metabolites in human plasma (abst–2013) http://link.springer.com/article/10.1007/s00216-012-6501-x
Exercise increases plasma THC concentrations in regular cannabis users (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24018317
Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period (abst–2013) http://www.sciencedirect.com/science/article/pii/S000145751300362X
Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24202191
Comparison between self-report of cannabis use and toxicological detection of  THC/THCCOOH in blood and THC in oral fluid in drivers in a roadside survey (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23939912
Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1561/full
Can Physical Exercise or Food Deprivation Cause Release of Fat-Stored Cannabinoids (full–2014) http://onlinelibrary.wiley.com/doi/10.1111/bcpt.12235/full
Performance, egg quality, and blood plasma chemistry of laying hens fed hempseed and hempseed oil (full–2014) http://ps.oxfordjournals.org/content/93/11/2827.long
Blood levels do not predict behavioral or physiological effects of Δ⁹-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251811/
Phase I and II Cannabinoid Disposition in Blood and Plasma of Occasional and Frequent Smokers Following Controlled Smoked Cannabis (full–2014)
http://www.clinchem.org/content/60/4/631.long
A One-Step Extraction Procedure for the Screening of Cocaine, Amphetamines and  Cannabinoids in Postmortem Blood Samples (full–2014)  https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bku039
Fasting and exercise increase plasma cannabinoid levels in THC pre-treated rats: an examination of behavioural consequences (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24696079
Determination of Δ9-tetrahydrocannabinolic acid A (Δ9-THCA-A) in whole blood and plasma by LC-MS/MS and application in authentic samples from drivers suspected of driving under the influence of cannabis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25173986
Spot them in the spot: analysis of abused substances using dried blood spots (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25383733
top
Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25127704
A quantitiative LC-MS/MS method for the measurement of arachidonic acid, prostanoids, endocannabinoids, N-acylethanolamines and steroids in human plasma (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25436483
Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol (full-2015) http://www.clinchem.org/content/61/6/850.long
Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects (full-2015) http://jat.oxfordjournals.org/content/39/7/497.long
Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users (full–2015) http://jat.oxfordjournals.org/content/39/8/580.long
Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of  Smoked Cannabis (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908634/
Controlled vaporized cannabis, with and without alcohol: subjective effects and oral
fluid-blood cannabinoid relationships (full–2015)  http://www.ncbi.nlm.nih.gov/pubmed/26257143
Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during  sustained abstinence and correlation with psychomotor performance (full–2015)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676741/
Driving Under the Influence of Marijuana Versus Driving and Dying Under the Influence
of Marijuana: A Comparison of Blood Concentrations of Δ9-Tetrahydrocannabinol, 11-
Hydroxy-Δ9-Tetrahydrocannabinol, 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol and
Other Cannabinoids in Arrested Drivers Versus Deceased Drivers (full–2015)  https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkv095
Concentrations of AB-CHMINACA and AB-PINACA and Driving Behavior in Suspected Impaired Driving Cases (full–2015) https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkv091
High-throughput salting-out assisted liquid-liquid extraction with acetonitrile for the determination of anandamide in plasma of hemodialysis patients with liquid chromatography tandem mass spectrometry (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25622579
Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use (abst–2015 http://www.ncbi.nlm.nih.gov/pubmed/25698515
Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25853390
Simultaneous determination of endocannabinoids in murine plasma and brain substructures by surrogate-based LC-MS/MS: Application in tumor-bearing mice (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25863017
Development of a simple and sensitive HPLC-UV method for the simultaneous determination of cannabidiol and Δ9-tetrahydrocannabinol in rat plasma (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26048666
Delays in DUI blood testing: Impact on cannabis DUI assessments (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/26066003
In vivo detection of the new psychoactive substance AM-694 and its metabolites (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26295909
Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids? (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26363623
top
Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26427296
In vitro stability of free and glucuronidated cannabinoids in blood and plasma collected in plastic gray-top sodium fluoride tubes following controlled smoked cannabis (abst–2015) http://link.springer.com/article/10.1007/s11419-015-0290-9
Case reports of synthetic cannabinoid XLR-11 associated fatalities (abst-2015)  http://www.ncbi.nlm.nih.gov/pubmed/25979131
Trends of novel psychoactive substances (NPSs) and their fatal cases (abst–2016) http://link.springer.com/article/10.1007/s11419-015-0286-5
Development of a rapid column-switching LC-MS/MS method for the quantification of THCCOOH and THCCOOH-glucuronide in whole blood for assessing cannabis consumption frequency (abst–2016) http://link.springer.com/article/10.1007/s00216-016-9311-8
Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27005853
The therapeutic use of cannabinoids: Forensic aspects (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27038587
Drug Recognition Expert (DRE) examination characteristics of cannabis impairment (abst–2016) http://www.sciencedirect.com/science/article/pii/S0001457516301191
Analysis of Omega-3 Fatty Acid Derived N-Acylethanolamines in Biological Matrices (abst–2016) http://link.springer.com/protocol/10.1007%2F978-1-4939-3539-0_4 Identification of the oleic acid ethanolamide (OEA) isomer cis-vaccenic acid ethanolamide (VEA) as a highly abundant 18:1 fatty acid ethanolamide in blood plasma from rats and humans (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27334716
Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB (abst–2016)  http://www.ncbi.nlm.nih.gov/pubmed/27345297
Cannabis Hyperemesis Syndrome in the Emergency Department: How Can a Specialized
Addiction Team Be Useful? A Pilot Study (abst–2016)  http://www.ncbi.nlm.nih.gov/pubmed/27485997
A novel microflow LC-MS method for the quantitation of endocannabinoids in serum  (abst–2016) http://www.sciencedirect.com/science/article/pii/S1570023216306663
Assessing cannabis consumption frequency: Is the combined use of free and  glucuronidated THCCOOH blood levels of diagnostic utility? (abst–2016)  https://www.ncbi.nlm.nih.gov/pubmed/27732768
Freeze-and-thaw stability and long-term-stability of 84 synthetic cannabinoids in serum  (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27863089
A systematic review of passive exposure to cannabis (abst–2016)  https://www.ncbi.nlm.nih.gov/pubmed/27883985
Free and Glucuronide Whole Blood Cannabinoids’ Pharmacokinetics after Controlled
Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional
Cannabis Users: Identification of Recent Cannabis Intake (abst–2016)  https://www.ncbi.nlm.nih.gov/pubmed/27899456
Dried haematic microsamples and LC-MS/MS for the analysis of natural and synthetic  cannabinoids (abst–2016)  http://www.sciencedirect.com/science/article/pii/S1570023216306171
Synthetic cannabinoid drug use as a cause or contributory cause of death (abst–2016)  https://www.ncbi.nlm.nih.gov/pubmed/26795398
Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition  and Relation to Pharmacodynamic Outcomes (brownies) (full–2017)  https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkx012
Health effects of exposure to second- and third-hand marijuana smoke: a systematic  review (full–2017) http://cmajopen.ca/content/5/4/E814.long
New challenges in toxicology of new psychoactive substances exemplified by fatal cases  after UR-144 and UR-144 with pentedrone administration determined by LC-ESI-MSMS in blood (full in Polish & English-2017) https://www.termedia.pl/Journal/-82/Artykul-31005
First evidence of the conversion of paracetamol to AM404 in human cerebrospinal fluid  (full–2017) https://www.dovepress.com/first-evidence-of-the-conversion-of-paracetamol-to-am404-in-human-cere-peer-reviewed-fulltext-articleJPR
Cannabis, alcohol and fatal road accidents (full–2017)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678710/
Are THC Levels in Oral Fluids and Blood Plasma Comparable after Oral Ingestion of  Edibles Containing Cannabis or THC? (1st page-2017)  http://clinchem.aaccjnls.org/content/early/2017/01/13/clinchem.2016.269795.long
Topical application of THC containing products is not able to cause positive cannabinoid  finding in blood or urine (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28122323
Evaluation of divided attention psychophysical task performance and effects on pupil  sizes following smoked, vaporized and oral cannabis administration (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28138971
Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28188235
Analysis of Drugs of Abuse in Cerumen – Correlation of Postmortem Analysis Results with Those for Blood, Urine and Hair (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28240418
Fatal Intoxication by 5F-ADB and Diphenidine: Detection, Quantification, and  Investigation of their Main Metabolic Pathways in Human by LC/MS/MS and LC/QTOFMS  (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28544560
The effect of antioxidants on the long-term stability of THC and related cannabinoids in
sampled whole blood (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28570781
An Atmospheric Pressure Ionization MS/MS Assay using Online Extraction for the  Analysis of 11 Cannabinoids and Metabolites in Human Plasma and Urine (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28640062
AB-CHMINACA-induced sudden death from non-cardiogenic pulmonary edema (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28707493
Postmortem Fluid and Tissue Concentrations of THC, 11-OH-THC and THC-COOH (abst–2017) https://academic.oup.com/jat/article-abstract/41/6/508/4055357/Postmortem-Fluid-and-Tissue-Concentrations-of-THC
ABCB1 C3435T polymorphism is associated with tetrahydrocannabinol blood levels in
heavy cannabis users (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28917442
Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid  Receptor Agonists: From Horizon Scanning to Notification (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/29038156
Methodology for controlled administration of smoked synthetic cannabinoids JWH-018  and JWH-073 (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0028390817305294?via%3Dihub
Simple and fast gas-chromatography mass spectrometry assay to assess delta 9-
tetrahydrocannabinol and cannabidiol in dogs treated with medical cannabis for canine
epilepsy (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/29173160
Identification of 5-Fluoro ADB in Human Whole Blood in Four Death Cases (abst–2017)  https://academic.oup.com/jat/advance-article-abstract/doi/10.1093/jat/bkx088/4656135?redirectedFrom=fulltext
Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to  Patients in a Hospital Setting (full–2018) https://link.springer.com/article/10.1007/s40268-017-0225-5


DRUG TESTING-BREATH TEST
Detection of δ(9)-tetrahydrocannabinol in exhaled breath collected from cannabis users (full–2011) http://jat.oxfordjournals.org/content/35/8/541.long
The prevalence of cannabis-involved driving in California (full–2011)  http://www.sciencedirect.com/science/article/pii/S0376871611004741
Detection of drugs of abuse in exhaled breath from users following recovery from intoxication (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23045289
Cannabinoids in Exhaled Breath following Controlled Administration of Smoked Cannabis (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24046200
Method validation and application of a liquid chromatography-tandem mass spectrometry method for drugs of abuse testing in exhaled breath (full–2015)  http://www.sciencedirect.com/science/article/pii/S1570023215000720
Application of drug testing using exhaled breath for compliance monitoring of drug addicts in treatment (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25562730
Ion mobility spectrometry for detection of Cannabis sativa L. metabolites from exhaled breath (abst–2015) https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0035-1565285
Δ9-Tetrahydrocannabinol concentrations in exhaled breath and physiological effects following cannabis intake – a pilot study using illicit cannabis (abst–2016) http://www.sciencedirect.com/science/article/pii/S0009912016300996
Determination of Cannabinoid Vapor Pressures to Aid in Vapor Phase Detection of  Intoxication (full–2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733806/
top


DRUG TESTING–DETECTION OF DRUGS
Potential exposures associated with indoor marijuana growing operations (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24116667
Detection of Illicit Drugs by Trained Honeybees (Apis mellifera) (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471073/
Development of Loop-Mediated Isothermal Amplification (LAMP) Assay for Rapid Detection of Cannabis sativa (link to PDF–2016) https://www.jstage.jst.go.jp/article/bpb/advpub/0/advpub_b16-00090/_article


DRUG TESTING–DIY CANNABINOID TESTING
DIY test to find high CBD plants grown from seeds (forum post–2015) http://forum.grasscity.com/medical-marijuana-usage-applications/1368614-diy-test-find-high-cbd-plantsgrown-seeds.html
Test THC and CBD at home (forum post–2015) http://www.marijuanagrowing.com/archive/index.php/t-8730.htm


DRUG TESTING-EDIBLES
Simultaneous determination of delta-9-tetrahydrocannabinol cannabidiol and cannabinol in edible oil using ultra performance liquid chromatography-tandem mass spectrometry (abst–2011) http://tinyurl.com/pmdcdp3
Simultaneous Analysis of Cannabinoid and Synthetic Cannabinoids in Dietary Supplements Using UPLC with UV and UPLC-MS-MS (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27185817
Stability of Tetrahydrocannabinol and Cannabidiol in Prepared Quality Control Medible Brownies (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27798074
Determination of cannabinoids in hemp nuts products in Taiwan by HPLC-MS/MS  coupled with chemometric analysis: Quality evaluation and a pilot human study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27590030
Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral
cannabis administration (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27647820
Are THC Levels in Oral Fluids and Blood Plasma Comparable after Oral Ingestion of
Edibles Containing Cannabis or THC? (1st page-2017)  http://clinchem.aaccjnls.org/content/early/2017/01/13/clinchem.2016.269795.long
Evaluation of cannabinoids concentration and stability in standardized preparations of
cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem
mass spectrometry (abst–2017) https://www.degruyter.com/view/j/cclm.ahead-of-print/cclm-2016-1060/cclm-2016-1060.xml
Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28188235


DRUG TESTING-HAIR*+
Hair analysis for Delta9-tetrahydrocannabinolic acid A – new insights into the mechanism of drug incorporation of cannabinoids into hair (abst-2010) http://www.ncbi.nlm.nih.gov/pubmed/20129747
11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid ethyl ester (THC-COOEt): unsuccessful search for a marker of combined cannabis and alcohol consumption (abst–2010) http://tinyurl.com/z5ddjfg
A study on the concentrations of 11-nor-Δ(9)-tetrahydrocannabinol-9-carboxylic acid (THCCOOH) in hair root and whole hair (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21497466
A comparative study on the concentrations of 11-nor-Δ(9)-tetrahydrocannabinol-9-carboxylic acid (THCCOOH) in head and pubic hair (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21802874
Detection and quantification of 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid in hair by GC/MS/MS in Negative Chemical Ionization mode (NCI) with a simple and rapid liquid/liquid extraction (abst–2011) http://tinyurl.com/jplo6t7
The standardization of results on hair testing for drugs of abuse: An inter-laboratory exercise in Lombardy Region, Italy (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/22018743/abstract/The_standardization_of_results_on_hair_testing_for_drugs_of_abuse:_An_interlaboratory_exercise_in_Lombardy_Region_Italy_
Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like  symptoms and psychological well-being (abst–2011)  http://www.ncbi.nlm.nih.gov/pubmed/21798112
Simultaneous analysis of several synthetic cannabinoids, THC, CBD and CBN, in hair by  ultra-high performance liquid chromatography tandem mass spectrometry. Method  validation and application to real samples. (link to PDF–2012)  https://iris.unito.it/handle/2318/99459#.WfYikmdTLQU
Determination of 22 synthetic cannabinoids in human hair by liquid chromatography tandem mass spectrometry (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22835826
top
Monitoring of chronic Cannabis abuse: An LC-MS/MS method for hair analysis (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23305934
Development and validation of an LC-MS/MS method for quantification of Δ9-tetrahydrocannabinolic acid A (THCA-A), THC, CBN and CBD in hair (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23378095
Determination of cocaine, cocaine metabolites and cannabinoids in single hairs by MALDI Fourier transform mass spectrometry – preliminary results (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23386550
Deposition of JWH-018, JWH-073 and their metabolites in hair and effect of hair pigmentation (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24162819
Diagnostic Value of Concentration Profiles of Glucocorticosteroids and Endocannabinoids in Hair (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23942543
Methadone and illegal drugs in hair from children with parents in maintenance treatment or suspected for drug abuse in a German community (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24263638
Screening for synthetic cannabinoids in hair by using LC-QTOF MS: A new and powerful approach to study the penetration of these new psychoactive substances in the population (full–2014) http://msl.sagepub.com/content/54/1/22.long
Utility of ELISA screening for the monitoring of abstinence from illegal and legal drugs in hair and urine (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1644/full
Utility of coloured hair for the detection of drugs and alcohol (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1654/full
Pediatric exposure to drugs of abuse by hair testing: monitoring 15 years of evolution in Spain (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143861/
Hair-based rapid analyses for multiple drugs in forensics and doping: application of dynamic multiple reaction monitoring with LC-MS/MS (full–2014) http://journal.chemistrycentral.com/content/8/1/73
top
Cannabinoid findings in children hair – what do they really tell us? An assessment in the light of three different analytical methods with focus on interpretation of Δ9-tetrahydrocannabinolic acid A concentrations (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1692/full
Is urine an alternative to cosmetically treated hair for the detection of drugs and alcohol? (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1629/full
Workplace drug testing in Italy: Findings about second-stage testing (abst–2014)  http://www.ncbi.nlm.nih.gov/pubmed/24652693
Hair analysis for THCA-A, THC and CBN after passive in vivo exposure to marijuana  smoke (abst–2014)  http://www.researchgate.net/publication/236185970_Hair_analysis_for_THCAA_THC_and_CBN_after_passive_in_vivo_exposure_to_marijuana_smoke
Proof of cannabis administration by sensitive detection of 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid in hair using selective methylation and application of liquid chromatography- tandem and multistage mass spectrometry (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1565/full
Workplace drug testing in Italy: Findings about second-stage testing (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24652693
Simultaneous determination of five naphthoylindole-based synthetic cannabinoids and metabolites and their deposition in human and rat hair (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25282599
Contribution of in utero drug exposure when interpreting hair results in young children (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25450508
Hair analysis as a tool to evaluate the prevalence of synthetic cannabinoids in different populations of drug consumers (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24115381
Ultra-structural hair alterations of drug abusers: a scanning electron microscopic investigation (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538045/
Finding cannabinoids in hair does not prove cannabis consumption (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595642/
Hair analysis for Δ(9) -tetrahydrocannabinolic acid A (THCA-A) and Δ(9) –
tetrahydrocannabinol (THC) after handling cannabis plant material (abst–2015)
https://www.researchgate.net/publication/278895867_Hair_analysis_for_D9-tetrahydrocannabinolic_acid_A_THCA-A_and_D9-tetrahydrocannabinol_THC_after_handling_cannabis_plant_material
Determination of XLR-11 and its metabolites in hair by liquid chromatography-tandem mass spectrometry (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26070160
Comparison of cannabinoids in hair with self-reported cannabis consumption in heavy, light and non-cannabis users (full–2016) http://onlinelibrary.wiley.com/doi/10.1111/dar.12412/full
Assessment of rates of recanting and hair testing as a biological measure of drug use in a general population sample of young people (full–2016) http://onlinelibrary.wiley.com/doi/10.1111/add.13645/full
Detection and Mapping of Cannabinoids in single hair samples through rapid
derivatization- Matrix-Assisted Laser Desorption Ionization Mass Spectrometry (full–2016) http://pubs.acs.org/doi/full/10.1021/acs.analchem.6b03551
Evidence based decontamination protocols for the removal of external Δ9-tetrahydrocannabinol (THC) from contaminated hair (abst–2016) http://www.fsijournal.org/article/S0379-0738%2815%2900504-6/abstract
Metabolites of synthetic cannabinoids in hair-proof of consumption or false friends for interpretation? (abst–2016) http://link.springer.com/article/10.1007%2Fs00216-016-9422-2
Endocannabinoid concentrations in hair are associated with PTSD symptom severity (abst–2016) http://www.psyneuen-journal.com/article/S0306-4530%2816%2930040-3/abstract
Influence of thermal hair straightening on cannabis and cocaine content in hair (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26826847
Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27005853
Highly sensitive quantification of unconjugated 11-nor-9-carboxy-Δ9- tetrahydrocannabinol in a cannabis user’s hair using micropulverized extraction (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27020617
Contactless decontamination of hair samples: cannabinoids (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27074965
Simultaneous HPLC-APCI-MS/MS quantification of endogenous cannabinoids and glucocorticoids in hair (abst–2016) http://www.sciencedirect.com/science/article/pii/S1570023216303786
A systematic review of passive exposure to cannabis (abst–2016)  https://www.ncbi.nlm.nih.gov/pubmed/27883985
Comparative Evaluation of Drug Deposition in Hair Samples Collected from Different
Anatomical Body Sites (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27979929
Drugs in hair Part I. Metabolisms of major drug classes (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28119266
Determination of AB-CHMINACA and its metabolites in human hair and their deposition in hair of abusers (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0731708517300067?via%3Dihub
The analysis of 132 novel psychoactive substances in human hair using a single step  extraction by tandem LC/MS (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28910664
Death by self-mutilation after oral cannabis consumption (abst–2017)  http://www.legalmedicinejournal.com/article/S1344-6223(17)30258-4/fulltext
Interpretation of cannabis findings in the hair of very young children: mission impossible (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/29189142
Instability and poor recovery of cannabinoids in urine, oral fluid, and hair (abst–2018) https://www.ncbi.nlm.nih.gov/pubmed/29273570


DRUG TESTING-INFANTS
Detection of In Utero Marijuana Exposure by GC–MS, Ultra-Sensitive ELISA and LC–
TOF–MS Using Umbilical Cord Tissue (full–2013)  http://jat.oxfordjournals.org/content/early/2013/07/09/jat.bkt052.full
Meconium Drug Testing in Multiple Births in the USA (full–2014)  https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bku061
Patterns of Drugs and Drug Metabolites Observed in Meconium: What Do They Mean?  (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25565668
Evaluating a switch from meconium to umbilical cord tissue for newborn drug testing: A
retrospective study at an academic medical center (abst–2016)  http://www.sciencedirect.com/science/article/pii/S0009912016306087
Analysis of Drugs of Abuse in Cerumen – Correlation of Postmortem Analysis Results with Those for Blood, Urine and Hair (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28240418
Comparison of umbilical cord tissue and meconium for the confirmation of in utero drug exposure (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0009912016307081
Assessment of tobacco, alcohol and cannabinoid metabolites in 645 meconium samples
of newborns compared to maternal self-reports (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28237885
Analysis of cannabinoids by liquid chromatography–mass spectrometry in milk, liver and hemp seed to ensure food safety (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0308814617301346
Development and validation of a liquid chromatography tandem mass spectrometry
method for the determination of cannabinoids and phase I and II metabolites in meconium (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0021967317304624?via%3Dihub
PLACENTA AS ALTERNATIVE SPECIMEN TO DETECT IN UTERO CANNABIS EXPOSURE: A SYSTEMATIC REVIEW OF THE LITERATURE (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0890623817300199
Interpretation of cannabis findings in the hair of very young children: mission impossible (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/29189142
Simultaneous accelerated solvent extraction and hydrolysis of 11-nor-Δ9-
tetrahydrocannabinol-9-carboxylic acid glucuronide in meconium samples for gas
chromatography-mass spectrometry analysis (abst–2017)
https://www.sciencedirect.com/science/article/pii/S1570023217319116?via%3Dihub


DRUG TESTING-OTHER*+
Simultaneous analysis of frequently used licit and illicit psychoactive drugs in breast milk by liquid chromatography tandem mass spectrometry (abst-2011) http://www.ncbi.nlm.nih.gov/pubmed/21330091
top
The Current Status of Sweat Testing for Drugs of Abuse: A review (link to PDF–2012) http://www.ncbi.nlm.nih.gov/pubmed/23244520
Chemiluminescence detection of cannabinoids and related compounds with acidic potassium permanganate (abst-2012) http://www.ncbi.nlm.nih.gov/pubmed/22461321
Simultaneous Quantification of Cocaine, Amphetamines, Opiates and Cannabinoids in Vitreous Humor (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/24225634
Chemical profiling of different hashish seizures by gas chromatography-mass  spectrometry and statistical methodology: a case report (abst–2013)  http://www.ncbi.nlm.nih.gov/pubmed/24008198
Potential exposures associated with indoor marijuana growing operations (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24116667
Detecting Cannabis Use on the Human Skin Surface via an Electronic Nose System (link to PDF-2014) http://www.mdpi.com/1424-8220/14/7/13256
An examination of the validity of the standardized field sobriety test in detecting drug impairment using data from the drug evaluation and classification program (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24345013
Can JWH-210 and JWH-122 be detected in adipose tissue four weeks after single oral drug administration to rats? (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24474420
Behaviours of psychotropic substances in indoor and outdoor environments of Rome, Italy (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24705952
Utilization of matrix-assisted laser desorption/ionization imaging mass spectrometry to search for cannabis in herb mixtures (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24838491
Development and validation of a sensitive UPLC-ESI-MS/MS method for the simultaneous quantification of 15 endocannabinoids and related compounds in milk and other biofluids (abst–2014) http://pubs.acs.org/doi/abs/10.1021/ac403352e
Psychotropic substances in indoor environments (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24997305
Detection and mapping of illicit drugs and their metabolites in fingermarks by MALDI MS and compatibility with forensic techniques (full–2015) http://www.nature.com/srep/2015/150629/srep11716/full/srep11716.html 
Detection of main metabolites of XLR-11 and its thermal degradation product in human hepatoma HepaRG cells and human urine (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25600155
Evaluation of an On-site Drug-testing Device for the Detection of Synthetic
Cannabinoids in Illegal Herbal Products (abst in English–2015)  http://www.ncbi.nlm.nih.gov/pubmed/25759062 (link to PDF in Japanese) https://www.jstage.jst.go.jp/article/yakushi/135/3/135_14-00247/_article/-char/ja/
Distribution of ∆9-Tetrahydrocannabinol and 11-Nor-9-Carboxy-∆9 -Tetrahydrocannabinol Acid in Postmortem Biological Fluids and Tissues From Pilots Fatally Injured in Aviation Accidents (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/25800046
Quantitation of Synthetic Cannabinoids in Plant Materials Using High Performance Liquid Chromatography with UV Detection (Validated Method) (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26175160
Development and validation of a LC/MS method for the determination of Δ9-
tetrahydrocannabinol and 11-carboxy-Δ9-tetrahydrocannabinol in the larvae of the  blowfly Lucilia sericata: Forensic applications (abst–2015)  http://www.scienceandjusticejournal.com/article/S1355-0306(15)00073-8/fulltext
The potential of infrared pupillography in routine police traffic checks (abst in English & German-2015) http://link.springer.com/article/10.1007/s00194-015-0023-8
top
Lipid Discovery by Combinatorial Screening and Untargeted LC-MS/MS (full–2016) http://www.nature.com/articles/srep27920
Sensitive Quantification of Cannabinoids in Milk by Alkaline Saponification–Solid Phase
Extraction Combined with Isotope Dilution UPLC–MS/MS (full–2016)  http://pubs.acs.org/doi/full/10.1021/acsomega.6b00253
Brain 2-Arachidonoylglycerol Levels Are Dramatically and Rapidly Increased Under Acute Ischemia-Injury Which Is Prevented by Microwave Irradiation (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27021494
Drug Recognition Expert (DRE) examination characteristics of cannabis impairment (abst–2016) http://www.sciencedirect.com/science/article/pii/S0001457516301191
Cannabis Use Surveillance By Sweat Analysis (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27465974
Use of Embryos Extracted from Individual Cannabis sativa Seeds for Genetic Studies and Forensic Applications (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27404624 Determination of Drugs of Abuse in a Single Sample of Human Teeth by a Gas Chromatography-Mass Spectrometry Method (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27681340
A systematic review of passive exposure to cannabis (abst–2016) http://www.fsijournal.org/article/S0379-0738(16)30493-5/abstract
Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using Ultra-High Performance Supercritical Fluid Chromatography/Photodiode Array-Mass Spectrometry  (full–2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549281/
Identification of a Widespread Palmitoylethanolamide Contamination in Standard  Laboratory Glassware (full–2017)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510777/
Broad-Scale Genetic Diversity of Cannabis for Forensic Applications (full–2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5249207/
Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28138971
Analysis of Drugs of Abuse in Cerumen – Correlation of Postmortem Analysis Results with Those for Blood, Urine and Hair (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28240418
Identification of Cannabis sativa L. using the 1-kbTHCA synthase-fluorescence in situ  hybridization probe (abst–2017) http://www.scienceandjusticejournal.com/article/S1355-0306(16)30109-5/fulltext
Analysis of cannabinoids by liquid chromatography–mass spectrometry in milk, liver and hemp seed to ensure food safety (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0308814617301346
Work place drug testing of police officers after THC exposure during large volume  cannabis seizures (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0379073817301342
Investigation of changes in endocannabinoids and N-acylethanolamides in biofluids, and their correlations with female infertility (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0021967317308798?via%3Dihub
PLACENTA AS ALTERNATIVE SPECIMEN TO DETECT IN UTERO CANNABIS EXPOSURE: A SYSTEMATIC REVIEW OF THE LITERATURE (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0890623817300199
Psychotropic substances in house dusts: a preliminary assessment (abst–2017)  https://link.springer.com/article/10.1007%2Fs11356-017-9549-5
Differentiation of Cannabis subspecies by THCA synthase gene analysis using RFLP  (abst–2017) http://www.jflmjournal.org/article/S1752-928X(17)30104-X/fulltext
Postmortem Fluid and Tissue Concentrations of THC, 11-OH-THC and THC-COOH (abst–2017) https://academic.oup.com/jat/article-abstract/41/6/508/4055357/Postmortem-Fluid-and-Tissue-Concentrations-of-THC


DRUG TESTING-ORAL +
Patent 7816143 Oral detection test for cannabinoid use (full-2010) http://www.freepatentsonline.com/7816143.pdf
Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry (full-2010)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2849720/
Direct detection of Delta9-tetrahydrocannabinol in saliva using a novel homogeneous competitive immunoassay with fluorescence quenching (abst-2010) http://www.ncbi.nlm.nih.gov/pubmed/20103093
Oral Fluid and Plasma Cannabinoid Ratios after Around-the-Clock Controlled Oral [Delta]9-Tetrahydrocannabinol Administration (full-2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836268/
Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration (full-2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842229/
top
Cannabinoids in oral fluid following passive exposure to marijuana smoke (full-2011) http://www.clinchem.org/content/57/8/1127.long
Oral Fluid Cannabinoids in Chronic, Daily Cannabis Smokers During Sustained, Monitored Abstinence (full-2011) http://www.ncbi.nlm.nih.gov/pubmed/21677094
The prevalence of cannabis-involved driving in California (full–2011)  http://www.sciencedirect.com/science/article/pii/S0376871611004741
US Patent Application 20110020945 – ORAL DETECTION TEST FOR CANNABINOID USE (full-2011) http://www.freshpatents.com/-dt20110127ptan20110020945.php
Synthetic cannabinoids in oral fluid. (link to PDF–2011)  http://jat.oxfordjournals.org/content/35/7/424.long
A validated method for the detection and quantitation of 50 drugs of abuse and medicinal drugs in oral fluid by gas chromatography-mass spectrometry (abst-2011) http://www.ncbi.nlm.nih.gov/pubmed/21411382
Alcohol, psychoactive drugs and fatal road traffic accidents in Norway: a case-control
study (abst–2011) http://www.sciencedirect.com/science/article/pii/S0001457510004112?via%3Dihub
A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid (full-2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456923/
Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612560/
Endocannabinoids measurement in human saliva as potential biomarker of obesity (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409167/?tool=pubmed
Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319321/
Cannabinoid Disposition in Oral Fluid after Controlled Smoked Cannabis (full–2012) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717347/
Ultra high performance liquid chromatography-electrospray ionization-tandem mass spectrometry screening method for direct analysis of designer drugs, “spice” and stimulants in oral fluid (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22939380
Influence of Ethanol on the Pharmacokinetic Properties of Δ9-Tetrahydrocannabinol in Oral Fluid (full–2013) http://jat.oxfordjournals.org/content/37/3/152.full
Current knowledge on cannabinoids in oral fluid (full–2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1514/full
11-Nor-9-carboxy-∆9-tetrahydrocannabinol quantification in human oral fluid by liquid chromatography-tandem mass spectrometry (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3773502/
Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758774/
Oral Fluid Cannabinoids in Chronic Cannabis Smokers during Oral Δ9-Tetrahydrocannabinol Therapy and Smoked Cannabis Challenge (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102264/
Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823692/
Detection of Synthetic Cannabinoids in Oral Fluid Using ELISA and LC-MS-MS (full–2013) https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkt067
Comparison between self-report of cannabis use and toxicological detection of THC/THCCOOH in blood and THC in oral fluid in drivers in a roadside survey (full–2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1517/full
top
Driving Under the Influence of Cannabis: Pitfalls, Validation, and Quality Control of a UPLC-MS/MS Method for the Quantification of Tetrahydrocannabinol in Oral Fluid Collected With StatSure, Quantisal, or Certus Collector (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23318281
LC/ESI-MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23535743
Micro extraction by packed sorbent coupled to liquid chromatography tandem mass spectrometry for the rapid and sensitive determination of cannabinoids in oral fluids (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23806358
Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24202191
Stability of 11 prevalent synthetic cannabinoids in authentic neat oral fluid samples: glass versus polypropylene containers at different temperatures (abst–2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1497/abstract
Concordance of self-reported drug use and saliva drug tests in a sample of emergency department patients (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120967/
Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362971/
Quantitative Measurement of XLR11 and UR-144 in Oral Fluid by LC-MS-MS (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24812645
Detection and Prevalence of Drug Use in Arrested Drivers Using the Dräger Drug Test
5000 and Affiniton DrugWipe Oral Fluid Drug Screening Devices (full–2014)  https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bku050
Assessment of different mouthwashes on cannabis oral fluid concentrations (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24453092
The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS (abst–2014)  http://www.ncbi.nlm.nih.gov/pubmed/24699310
Evaluation of Δ9 -tetrahydrocannabinol detection using DrugWipe5S® screening and
oral fluid quantification after Quantisal™ collection for roadside drug detection via a
controlled study with chronic cannabis users (abst–2014)  http://www.ncbi.nlm.nih.gov/pubmed/24753449
Detection Time for THC in Oral Fluid after Frequent Cannabis Smoking (abst–2014)  http://www.ncbi.nlm.nih.gov/pubmed/24819969
Cannabinoids determination in oral fluid by SPME-GC/MS and UHPLC-MS/MS and its application on suspected drivers (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25498928
Current knowledge on cannabinoids in oral fluid (abst–2014) http://www.ingentaconnect.com/search/article;jsessionid=95az9ydub2yj.victoria?option1=tka&value1=cannabinoid&pageSize=10&index=6
top
Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug
Concentrations and Corresponding Subjective Effects (full–2015)  http://jat.oxfordjournals.org/content/39/7/497.long
Impact of oral fluid collection device on cannabinoid stability following smoked
cannabis (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282833/
Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships (full–2015)  http://www.ncbi.nlm.nih.gov/pubmed/26257143
Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use  (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25698515
Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices  (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25853390
Disposable screen printed sensor for the electrochemical detection of delta-9-
tetrahydrocannabinol in undiluted saliva (full–2016)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722664/
Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in
Occasional Cannabis Smokers After Smoking Cannabis Cigarette (link to download–2016) https://ejournals.library.ualberta.ca/index.php/JPPS/article/view/28326/20877
Water-compatible imprinted pills for sensitive determination of cannabinoids in urine and oral fluid (abst–2016)  http://www.sciencedirect.com/science/article/pii/S0021967315017616
Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27005853
Small Molecule Detection in Saliva Facilitates Portable Tests of Marijuana Abuse (abst–2016) http://pubs.acs.org/doi/abs/10.1021/acs.analchem.6b01688
Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27647820
Illicit Drugs in Oral Fluid: Evaluation of Two Collection Devices (abst–2016)
https://www.ncbi.nlm.nih.gov/pubmed/27681339
A systematic review of passive exposure to cannabis (abst–2016)
https://www.ncbi.nlm.nih.gov/pubmed/27883985
Fluorescence-based lateral flow assays for rapid oral fluid roadside detection of cannabis use (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27862053
Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes (brownies) (full–2017) https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkx012
Are THC Levels in Oral Fluids and Blood Plasma Comparable after Oral Ingestion of Edibles Containing Cannabis or THC? (1st page-2017)  http://clinchem.aaccjnls.org/content/early/2017/01/13/clinchem.2016.269795.long
Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28188235
Evaluation of Oral Fluid as a Specimen for DUID (abst–2017)
https://www.ncbi.nlm.nih.gov/pubmed/28633318
Pharmacokinetic Properties of the synthetic cannabinoid JWH-018 in oral fluid after inhalation (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28967189
Oral fluid vs. Urine Analysis to Monitor Synthetic Cannabinoids and Classic Drugs Recent Exposure (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/29173162
Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to
Patients in a Hospital Setting (full–2018) https://link.springer.com/article/10.1007/s40268-017-0225-5
Instability and poor recovery of cannabinoids in urine, oral fluid, and hair (abst–2018) https://www.ncbi.nlm.nih.gov/pubmed/29273570
Mobile contingency management as an adjunctive treatment for co-morbid cannabis use  disorder and cigarette smoking (abst–2018)
https://www.sciencedirect.com/science/article/pii/S0306460317304604?via%3Dihub


DRUG TESTING-POSTMORTEM
Postmortem redistribution of THC in the pig (abst–2010)  http://www.ncbi.nlm.nih.gov/pubmed/20052591
Postmortem redistribution of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OHTHC), and 11-nor-9-carboxy-THC (THCCOOH) (full–2011)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413259/
Cannabinoids in postmortem toxicology (link to PDF–2011)  http://jat.oxfordjournals.org/content/35/7/394.long
The inverse agonist effect of rimonabant on G protein activation is not mediated by the
cannabinoid CB1 receptor: Evidence from postmortem human brain (abst–2012)  http://www.sciencedirect.com/science/article/pii/S0006295211008161
Cannabis misinterpretation and misadventure in a coroner’s court (abst–2012)  http://journals.sagepub.com/doi/full/10.1258/msl.2011.011087
K2 Toxicity: Fatal Case of Psychiatric Complications Following AM2201 Exposure (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319529/
Quantification of endocannabinoids in postmortem brain of schizophrenic subjects  (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23800614
A One-Step Extraction Procedure for the Screening of Cocaine, Amphetamines and
Cannabinoids in Postmortem Blood Samples (full–2014)  https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bku039
Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a
human cadaver (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525191/
Driving Under the Influence of Marijuana Versus Driving and Dying Under the Influence
of Marijuana: A Comparison of Blood Concentrations of Δ9-Tetrahydrocannabinol, 11-
Hydroxy-Δ9-Tetrahydrocannabinol, 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol and  Other Cannabinoids in Arrested Drivers Versus Deceased Drivers (full–2015)  https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkv095
Distribution of ∆9 -Tetrahydrocannabinol and 11-Nor-9-Carboxy-∆9-Tetrahydrocannabinol Acid in Postmortem Biological Fluids and Tissues From Pilots
Fatally Injured in Aviation Accidents (abst–2015)  http://www.ncbi.nlm.nih.gov/pubmed/25800046
Investigation of a recently detected THCCOOH isomer: Post mortem findings and  comparison with Δ(8)-THCCOOH (abst–2015)  https://www.ncbi.nlm.nih.gov/pubmed/26409163
Case reports of synthetic cannabinoid XLR-11 associated fatalities (abst–2015)  http://www.ncbi.nlm.nih.gov/pubmed/25979131
Analysis of Drugs of Abuse in Cerumen – Correlation of Postmortem Analysis Results
with Those for Blood, Urine and Hair (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28240418
Postmortem Fluid and Tissue Concentrations of THC, 11-OH-THC and THC-COOH (abst–2017) https://academic.oup.com/jat/article-abstract/41/6/508/4055357/Postmortem-Fluid-and-Tissue-Concentrations-of-THC
Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and ABCHMINACA (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/29133010
Interpretation of cannabis findings in the hair of very young children: mission impossible (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/29189142
Teens and Spice: A Review of Adolescent Fatalities Associated with Synthetic  Cannabinoid Use (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/29194599
Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients (abst–2018)  https://www.ncbi.nlm.nih.gov/pubmed/29334787


DRUG TESTING-QUALITY CONTROL
Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for  chemotaxonomic and drug standardization purposes (abst–2010)  http://www.sciencedirect.com/science/article/pii/S003194221000381X
How Accurate is Potency Testing? (download–2011)  http://www.canorml.org/RingTestOShaughnessys_Aut11.pdf
Is today’s marijuana more potent simply because it’s fresher? (abst–2012)  http://www.ncbi.nlm.nih.gov/pubmed/23169764
Chemists Analyze Cannabis For Safety And Potency (article–2013) http://cen.acs.org/articles/91/i49/Chemists-Analyze-Cannabis-Safety-Potency.html
Method for the Analysis of Cannabinoids and Terpenes in Cannabis (download–2015)  https://phytofacts.info/resources/methods.pdf
Metagenomic analysis of medicinal Cannabis samples; pathogenic bacteria, toxigenic fungi, and beneficial microbes grow in culture-based yeast and mold tests (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089129/
Analysis of a commerical marijuana e-cigarette formulation (abst–2016) (This article has a delayed release and will be available in PMC on June 1, 2017) https://www.ncbi.nlm.nih.gov/pubmed/27059691
Chapter 4 – Analytical Methods in Formulation Development and Manufacturing (abst–2016) http://www.sciencedirect.com/science/article/pii/B9780128046463000047
Chapter 5 – Quality Control and Stability Assessment (abst–2016) http://www.sciencedirect.com/science/article/pii/B9780128046463000059
Quality Control of Traditional Cannabis Tinctures: Pattern, Markers, and Stability (full–2017) http://www.mdpi.com/2218-0532/84/3/567/htm
Leaner and greener analysis of cannabinoids (full–2017)  http://link.springer.com/article/10.1007%2Fs00216-017-0256-3
Endogenous synthesis of pyrethrins by cannabis (not all strains, just medihaze, so far)
(link to PDF–2017) http://www.biorxiv.org/content/early/2017/07/28/169417
Development of a rapid LC-MS/MS method for the quantification of cannabidiol,
cannabidivarin, Δ9-tetrahydrocannabivarin and cannabigerol in mouse peripheral tissues (abst–2017) http://pubs.acs.org/doi/abs/10.1021/acs.analchem.7b01094
Evaluation of cannabinoids concentration and stability in standardized preparations of
cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem
mass spectrometry (abst–2017) https://www.degruyter.com/view/j/cclm.ahead-of-print/cclm-2016-1060/cclm-2016-1060.xml
Qualitative and quantitative measurement of cannabinoids in cannabis using modified
HPLC/DAD method (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0731708517311391?via%3Dihub
A Metabolomic Approach Applied to a Liquid Chromatography Coupled to High Resolution Tandem Mass Spectrometry Method (HPLC-ESI-HRMS/MS): Towards the
Comprehensive Evaluation of the Chemical Composition of Cannabis Medicinal Extracts (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28915313
A review of methods for the chemical characterization of cannabis natural products (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28986974
Cannabinoids concentration variability in cannabis olive oil galenic preparations (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/29057480
Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics  studies of cannabidiolic acid (CBDA) (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0731708517322367?via%3Dihub
Therapeutic use of Δ9-THC and cannabidiol: evaluation of a new extraction procedure  for the preparation of cannabis-based olive oil (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/29189144


DRUG TESTING–SECOND-HAND SMOKE
Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to Cannabis  smoke in a coffee shop (full-2010)  http://jat.oxfordjournals.org/content/34/4/196.long
Interpretation of blood analysis data found after passive exposure to cannabis (abst–2010) http://www.unboundmedicine.com/medline/ebm/record/20506708/abstract/%5BInterpretation_of_blood_analysis_data_found_after_passive_exposure_to_cannabis%5D_
Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled
around-the-clock oral THC administration (full-2011)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842229/
Cannabinoids in oral fluid following passive exposure to marijuana smoke (full–2011) http://www.clinchem.org/content/57/8/1127.long
Oral Fluid Cannabinoids in Chronic, Daily Cannabis Smokers During Sustained,
Monitored Abstinence (full–2011) http://clinchem.aaccjnls.org/content/57/8/1127.long
Current knowledge on cannabinoids in oral fluid (full–2013)  http://onlinelibrary.wiley.com/doi/10.1002/dta.1514/full
11-Nor-9-carboxy-∆9-tetrahydrocannabinol quantification in human oral fluid by liquid
chromatography-tandem mass spectrometry (full–2013)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3773502/
Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic
frequent and occasional smokers (full–2013)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823692/
Assessment of different mouthwashes on cannabis oral fluid concentrations (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24453092
Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and
confirmation results (full–2015)  http://www.researchgate.net/publication/267043767_NonSmoker_Exposure_to_Secondhand_Cannabis_Smoke._I._Urine_Screening_and_Confirmation_Results
Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on  the physiological, subjective, and behavioral/cognitive effects (full–2015)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747424/
Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug  Concentrations and Corresponding Subjective Effects (full–2015)  http://jat.oxfordjournals.org/content/39/7/497.long
A systematic review of passive exposure to cannabis (abst–2016)  https://www.ncbi.nlm.nih.gov/pubmed/27883985
Health effects of exposure to second- and third-hand marijuana smoke: a systematic
review (full–2017) http://cmajopen.ca/content/5/4/E814.long
Interpretation of cannabis findings in the hair of very young children: mission impossible (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/29189142


DRUG TESTING-URINE*
Urine Drug Screening: A Valuable Office Procedure (full–2010) http://www.aafp.org/afp/2010/0301/p635.html
Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815025/?tool=pubmed
Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461262/pdf/nihms246130.pdf
Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop (full-2010) http://jat.oxfordjournals.org/content/34/4/196.long
top
Commonly prescribed medications and potential false-positive urine drug screens (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20689123
Testing for cannabis in the work-place: a review of the evidence (abst–2010)  http://www.ncbi.nlm.nih.gov/pubmed/20402984
Quantitation of Total 11-Nor-9-Carboxy-Delta 9-Tetrahydrocannabinol in Urine and Blood Using Gas Chromatography-Mass Spectrometry (GC-MS) (abst-2010) http://marijuana.researchtoday.net/archive/7/1/2746.htm
Detection of cannabigerol and its presumptive metabolite in human urine after Cannabis consumption (abst-2010) http://www.ncbi.nlm.nih.gov/pubmed/20614687
Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls (abst-2010) http://www.ncbi.nlm.nih.gov/pubmed/20872894
Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105467/
Efavirenz interference in urine screening immunoassays for tetrahydrocannabinol (full–2011) http://acb.sagepub.com/content/49/2/194.long
Zinc Reduces the Detection of Cocaine, Methamphetamine, and THC by ELISA Urine Testing (full–2011) We need 8 to 11 mg of zinc daily; over 40 mg/day can cause zinc poisoning http://jat.oxfordjournals.org/content/35/6/333.long
Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2  (JWH-018) metabolites (link to PDF–2011)  http://jat.oxfordjournals.org/content/35/7/487.long
Prolonged excretion half-life of 11-nor-9-carboxy-Δ⁹-THC following cessation in a chronic, heavy marijuana user: implications for liver transplant assessment (1st page-2011) http://www.psychosomaticsjournal.com/article/S0033-3182%2810%2900028-9/abstract
A method for CP 47, 497 a synthetic non-traditional cannabinoid in human urine using liquid chromatography tandem mass spectrometry (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21233028
Evaluating the athlete’s claim of an unintentional positive urine drug test (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/23531893
Three cases of “spice” exposure (abst–2011)  http://www.ncbi.nlm.nih.gov/pubmed/21740143
Adolescent Exposure of JWH-018 “Spice” Produces Subtle Effects on Learning and Memory Performance in Adulthood (full–2012) http://file.scirp.org/Html/2-3900080_19505.htm
Unresolved Discrepancies between Cannabinoid Test Results for Infant Urine (full–2012) http://www.clinchem.org/content/58/9/1364.full
Characterization of In Vitro Metabolites of CP 47,497, a Synthetic Cannabinoid, in Human Liver Microsomes by LC-MS/MS (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22931239
Impact of Lowering Confirmatory Test Cutoff Value in Pre-Enlistment Urine Cannabinoids Screening: About Five Years’ Experience in the French Gendarmerie (abst-2012) http://www.ncbi.nlm.nih.gov/pubmed/22933660
Comparison of Random and Postaccident Urine Drug Tests in Southern Indiana Coal Miners (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22895464
Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22465236
top
Cannabis, possible cardiac deaths and the coroner in Ireland (abst–2012)  https://www.ncbi.nlm.nih.gov/pubmed/22231902
Qualitative Confirmation of 9 Synthetic Cannabinoids and 20 Metabolites in Human Urine Using LC-MS/MS and Library Search (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874406/
Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703206/
Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography tandem mass spectrometry (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963402/
Efavirenz does not cause false-positive urine cannabis test in HIV-infected patients on Highly Active Anti-Retroviral Therapy (full–2013) http://www.e-mjm.org/2013/v68n3/Efavirenz.pdf
Urinary Cannabinoid Disposition in Occasional and Frequent Smokers: Is THC Glucuronide in Sequential Urine Samples a Marker of Recent Use in Frequent Smokers? (full–2013) http://www.clinchem.org/content/60/2/361.long
The accuracy of self-reported data concerning recent cannabis use in the French armed forces (full–2013) http://eurpub.oxfordjournals.org/content/23/2/328.long
Validation of a Novel Immunoassay for the Detection of Synthetic Cannabinoids and Metabolites in Urine Specimens (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23625703
Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized
medical marijuana: 125 dogs (2005-2010) (abst-2013)  https://www.researchgate.net/publication/233874975_Evaluation_of_trends_in_marijuana_toxicosis_in_dogs_living_in_a_state_with_
legalized_medical_marijuana_125_dogs_2005-2010
Monitoring of urinary metabolites of JWH-018 and JWH-073 in legal cases (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23890611
Molecularly imprinted solid phase extraction for simultaneous determination of Δ(9)-tetrahydrocannabinol and its main metabolites by gas chromatography-mass spectrometry in urine samples (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23890655
Targeted Metabolomic Approach for Assessing Human Synthetic Cannabinoid Exposure and Pharmacology (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23987522
An in vitro experiment on the interaction of charcoal or wheat bran with 11-nor-9-carboxy-Δ9-tetrahydrocannabinol and its glucuronide (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24077855
Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23042760
Analysis of AM-2201 and metabolites in a drugs and driving case (abst–2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1535/abstract
Exercise increases plasma THC concentrations in regular cannabis users (abst-2013)  http://www.ncbi.nlm.nih.gov/pubmed/24018317
Utility of ELISA screening for the monitoring of abstinence from illegal and legal drugs in hair and urine (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1644/full
Can Physical Exercise or Food Deprivation Cause Release of Fat-Stored Cannabinoids? (full–2014) http://onlinelibrary.wiley.com/doi/10.1111/bcpt.12235/full
top
In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259566/
Is urine an alternative to cosmetically treated hair for the detection of drugs and alcohol? (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1629/full
Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine (full-2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127333/
Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363290/
Enzyme-Linked Immunosorbent Assay (ELISA) for the Detection of Use of the Synthetic Cannabinoid Agonists UR-144 and XLR-11 in Human Urine (full–2014) https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bku049
False-Positive Interferences of Common Urine Drug Screen Immunoassays: A Review (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24986836
Urine Toxicology Screen in Multiple Sleep Latency Test: The Correlation of Positive
Tetrahydrocannabinol, Drug Negative Patients, and Narcolepsy (full–2014)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298782/
Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1702/full
LC-QTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24424965
Workplace drug testing in Italy: Findings about second-stage testing (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24652693
UPLC-ESI-Q-TOF-MSE identification of urinary metabolites of the emerging sport nutrition supplement methoxyisoflavone in human subjects (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24742771
Cocaine’s fall and marijuana’s rise: questions and insights based on new estimates of consumption and expenditures in US drug markets (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25039446
Determination of major metabolites of MAM-2201 and JWH-122 in in vitro and in vivo studies to distinguish their intake (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25195129
Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25263309
Marijuana and workplace safety: an examination of urine drug tests (abst–2014)  https://www.ncbi.nlm.nih.gov/pubmed/24467478
Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results (full–2015) http://www.researchgate.net/publication/267043767_NonSmoker_Exposure_to_Secondhand_Cannabis_Smoke._I._Urine_Screening_and_Confirmation_Results
13-Year-Old Girl With Recurrent, Episodic, Persistent Vomiting: Out of the Pot and Into the Fire (full–2015) http://pediatrics.aappublications.org/content/135/4/e1060.long
Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747424/
Detection Times of Carboxylic Acid Metabolites of the Synthetic Cannabinoids JWH-018 and JWH-073 in Human Urine (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25737323
Prevalence of psychotropic drug use in military police units (full–2015) http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-81232015000601843&lng=en&nrm=iso&tlng=en
Detection of main metabolites of XLR-11 and its thermal degradation product in human hepatoma HepaRG cells and human urine (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25600155
top
Evaluation of an On-site Drug-testing Device for the Detection of Synthetic Cannabinoids in Illegal Herbal Products (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25759062
Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use (abst–2015 http://www.ncbi.nlm.nih.gov/pubmed/25698515
Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25853390
Rapid elimination of Carboxy-THC in a cohort of chronic cannabis users (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26233612
Comparison of Common Immunoassay Kits for Effective Application in Workplace Drug Urinalysis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26270150
In vivo detection of the new psychoactive substance AM-694 and its metabolites (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26295909
Workplace drug testing on urine samples: evidence for improving efficacy of a first-level screening programme (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26384263
Analysis of Cannabinoids and Their Metabolites in Human Urine (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26411292
Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26427296
Importance of Urinary Drug Screening in the Multiple Sleep Latency Test and
Maintenance of Wakefulness Test (full–2016)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155193/
Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette (link to download–2016) https://ejournals.library.ualberta.ca/index.php/JPPS/article/view/28326/20877
Detecting biomarkers of secondhand marijuana smoke in young children (link to PDF– 2016) http://www.nature.com/pr/journal/vaop/naam/abs/pr2016261a.html
Water-compatible imprinted pills for sensitive determination of cannabinoids in urine and oral fluid (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26718187
Determination of urinary metabolites of XLR-11 by liquid chromatography–quadrupole time-of-flight mass spectrometry (abst–2016) http://link.springer.com/article/10.1007/s00216-015-9116-1
Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27005853
The therapeutic use of cannabinoids: Forensic aspects (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27038587
Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated using LC-HRMS/MS: Do they reflect patterns in humans? (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27328899
Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27345297
Synthetic cannabinoids to avoid urine drug screens: Implications for contingency management and other treatments for drug dependence (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27424166
Determination of cannabinoids in hemp nuts products in Taiwan by HPLC-MS/MS coupled with chemometric analysis: Quality evaluation and a pilot human study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27590030
Adulterants in Urine Drug Testing (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27645818
Interpretation of Workplace Tests for Cannabinoids (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27686239
Antibody Fragments for On-Site Testing of Cannabinoids Generated via in Vitro Affinity  Maturation (full–2017) https://www.jstage.jst.go.jp/article/bpb/40/2/40_b16-00669/_html
Clinical Interpretation of Urine Drug Tests (full–2017)  http://www.mayoclinicproceedings.org/article/S0025-6196(16)30825-4/fulltext
Commercial herbal medicines used as African traditional medicines: Ngoma Herbal
Tonic Immune Booster interferes with a rapid urine drug screening test (full-2017)  https://www.ajol.info/index.php/samj/article/view/161438/151005
Synthetic Cannabinoid and Mitragynine Exposure of Law Enforcement Agents During
the Raid of an Illegal Laboratory — Nevada, 2014 (full–2017)  https://www.cdc.gov/mmwr/volumes/66/wr/mm6647a3.htm
Health effects of exposure to second- and third-hand marijuana smoke: a systematic
review (full–2017) http://cmajopen.ca/content/5/4/E814.long
Trends in Self-reported and Biochemically Tested Marijuana Use Among Pregnant
Females in California From 2009-2016 (1st page–2017)  https://jamanetwork.com/journals/jama/article-abstract/2667052?redirect=true
Topical application of THC containing products is not able to cause positive cannabinoid
finding in blood or urine (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28122323
Immunoassay screening in urine for synthetic cannabinoids – an evaluation of the
diagnostic efficiency (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28130957
Analysis of Drugs of Abuse in Cerumen – Correlation of Postmortem Analysis Results
with Those for Blood, Urine and Hair (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28240418
Detection of the recently emerged synthetic cannabinoid 5 F-MDMB-PICA in ‘legal high’  products and human urine samples (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28371476
Work place drug testing of police officers after THC exposure during large volume
cannabis seizures (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0379073817301342
An Atmospheric Pressure Ionization MS/MS Assay using Online Extraction for the
Analysis of 11 Cannabinoids and Metabolites in Human Plasma and Urine (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28640062
Impact of Regular Cannabis Use on Biomarkers of Lower Urinary Tract Function (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28827195
Postmortem Fluid and Tissue Concentrations of THC, 11-OH-THC and THC-COOH (abst–2017) https://academic.oup.com/jat/article-abstract/41/6/508/4055357/Postmortem-Fluid-and-Tissue-Concentrations-of-THC
Cross-Reactivity of Pantoprazole with Three Commercial Cannabinoids Immunoassays in Urine (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28985315
Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid
Receptor Agonists: From Horizon Scanning to Notification (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/29038156
Up in Smoke: Uncovering a Lack of Evidence for Proton Pump Inhibitors as a Source of
Tetrahydrocannibol Immunoassay False Positives (abst-2017)  https://academic.oup.com/painmedicine/advance-article-abstract/doi/10.1093/pm/pnx266/4604941?redirectedFrom=fulltext
Prevalence of illicit drug use at the end of pregnancy: a cross-sectional study at the time
of birth (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28176511
Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine
Following Acute Oral Cannabis Ingestion in Healthy Adults (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/29300962
Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to  Patients in a Hospital Setting (full–2018) https://link.springer.com/article/10.1007/s40268-017-0225-5
Instability and poor recovery of cannabinoids in urine, oral fluid, and hair (abst–2018) https://www.ncbi.nlm.nih.gov/pubmed/29273570


DRUG TESTING-WASTEWATER/SEWAGE
The current status of community drug testing via the analysis of drugs and drug metabolites in sewage (full–2011) http://www.ntnu.no/ojs/index.php/norepid/article/view/1421/1274
Evaluation of drugs of abuse use and trends in a prison through wastewater analysis (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/20655111/abstract/Evaluation_of_drugs_of_abuse_use_and_trends_in_a_prison_through_wastewater_analysis_
top
Evaluation of the presence of drugs of abuse in tap waters (abst–2011) http://www.sciencedirect.com/science/article/pii/S0045653511005868
Refining the estimation of illicit drug consumptions from wastewater analysis: coanalysis of prescription pharmaceuticals and uncertainty assessment (abst–2011) http://www.sciencedirect.com/science/article/pii/S0043135411003150
Profiles of illicit drug use during annual key holiday and control periods in Australia: wastewater analysis in an urban, a semi-rural and a vacation area (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23072541
Investigation of drugs of abuse and relevant metabolites in Dutch sewage water by liquid chromatography coupled to high resolution mass spectrometry (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22784865
Using quantitative wastewater analysis to measure daily usage of conventional and emerging illicit drugs at an annual music festival (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/dar.12061/full
Using biomarkers in wastewater to monitor community drug use: A conceptual approach for dealing with new psychoactive substances (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24412561
Illicit and abused drugs in sewage sludge: Method optimization and occurrence (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24275487
Wastewater analysis reveals regional variability in exposure to abused drugs and opioids in Finland (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24275228
Spatial differences and temporal changes in illicit drug use in Europe quantified by wastewater analysis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24861844
Evaluation of the Efficacy of the Sewage Treatment Plant of Toledo, Spain in the  Elimination of Drugs of Abuse and the Estimation of Consumption (abst–2014)  http://www.ncbi.nlm.nih.gov/pubmed/24914867 (click “Full Text Links” for download of PDF in Spanish)

Improvements in analytical methodology for the determination of frequently consumed illicit drugs in urban wastewater (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24752696
Analysis of new classes of recreational drugs in sewage: Synthetic cannabinoids and amphetamine-like substances (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1461/full
Application of a sewage-based approach to assess the use of ten illicit drugs in four Chinese megacities (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24485909
National study of illicit drug use in Slovakia based on wastewater analysis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25046607
Trend analysis of anonymised pooled urine from portable street urinals in central London identifies variation in the use of novel psychoactive substances (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24506433
Occurrence and removal of drugs of abuse in Wastewater Treatment Plants of Valencia (Spain) (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25108491
Illicit drug consumption estimated by wastewater analysis in different districts of Milan: A case study (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25545943
Analysis of drugs of abuse by online SPE-LC high resolution mass spectrometry: Communal assessment of consumption (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25553546
top
Monitoring substance use in prisons: Assessing the potential value of wastewater analysis (abst–2014) http://www.scienceandjusticejournal.com/article/S1355-0306%2814%2900093-8/abstract
Simultaneous determination of 148 pharmaceuticals and illicit drugs in sewage sludge  based on ultrasound-assisted extraction and liquid chromatography-tandem mass  spectrometry (full–2015) https://link.springer.com/article/10.1007%2Fs00216-015-8540-6
Detection of physiological activities of G protein-coupled receptor-acting pharmaceuticals in wastewater (abst–2015)  http://www.ncbi.nlm.nih.gov/pubmed/25556879
Simultaneous determination of 148 pharmaceuticals and illicit drugs in sewage sludge based on ultrasound-assisted extraction and liquid chromatography-tandem mass spectrometry (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25716466
Multi-residue determination of 10 selected new psychoactive substances in wastewater samples by liquid chromatography-tandem mass spectrometry (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26452866
Zerovalent iron and iron(VI): Effective means for the removal of psychoactive pharmaceuticals and illicit drugs from wastewaters (abst–2015)
http://www.ncbi.nlm.nih.gov/pubmed/26376114
Wastewater analysis and drugs — a European multi-city study (link to PDF–2016) http://www.emcdda.europa.eu/topics/pods/waste-water-analysis
Assessing geographical differences in illicit drug consumption-A comparison of results from epidemiological and wastewater data in Germany and Switzerland (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26896168
Population surveys compared with wastewater analysis for monitoring illicit drug consumption in Italy in 2010-2014 (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26875670
Screening new psychoactive substances in urban wastewater using high resolution mass spectrometry (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27086019
Temporal trends in drug use in Adelaide, South Australia by wastewater analysis (abst–2016) http://www.sciencedirect.com/science/article/pii/S0048969716308853
Estimation of illicit drug use in the main cities of Colombia by means of urban wastewater analysis (abst–2016) http://www.sciencedirect.com/science/article/pii/S0048969716310087
Drugs of abuse and alcohol consumption among different groups of population on the Greek Island of Lesvos through sewage-based epidemiology (abst–2016) http://www.sciencedirect.com/science/article/pii/S0048969716308233
Estimating population size in wastewater-based epidemiology. Valencia metropolitan area as a case study (abst–2016) http://www.sciencedirect.com/science/article/pii/S0304389416305246
A comparison between wastewater-based drug data and an illicit drug use survey in a selected community (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27450319 Integrating environmental and self-report data to refine cannabis prevalence estimates in a major urban area of Switzerland (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27455466
Occurrence of illicit drugs and selected pharmaceuticals in Slovak municipal wastewater (abst–2016) http://link.springer.com/article/10.1007%2Fs11356-016-7415-5
Applying sewage epidemiology approach to estimate illicit drug consumption in a  tropical context: Bias related to sewage temperature and pH (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0048969717301262
Occurrence and fate of illicit drugs and pharmaceuticals in wastewater from two wastewater treatment plants in Costa Rica (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0048969717310471
Illicit drug consumption in school populations measured by wastewater analysis (abst–2017) http://www.drugandalcoholdependence.com/article/S0376-8716(17)30304-6/fulltext
Five-year monitoring of 19 illicit and legal substances of abuse at the inlet of a  wastewater treatment plant in Barcelona (NE Spain) and estimation of drug consumption patterns and trends (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0048969717318296
Occurrence of illicit drugs in water and wastewater, and their removal during wastewater treatment (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0043135417306413
Illicit drugs consumption evaluation by wastewater-based epidemiology in the urban area of Palermo city (Italy) (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28956797


DYSAUTONOMIC SYNDROME
Short-Term Efficacy of CBD-Enriched Hemp Oil in Girls with Dysautonomic Syndrome
after Human Papillomavirus Vaccination (link to PDF–2017)  https://www.ima.org.il/IMAJ/ViewArticle.aspx?aId=4042


DYSKINESIA*+
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats (abst-2010) http://www.ncbi.nlm.nih.gov/pubmed/20888328
Tardive Dystonia and the Use of Cannabis (letter-forum repost-2010) http://www.420magazine.com/forums/dystonia/169902-tardive-dystonia-use-cannabis.html
Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia (full-2011) http://www.nature.com/tpj/journal/v12/n3/full/tpj201093a.html
Effects of cannabinoid CB(1) receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys (abst-2011) http://www.ncbi.nlm.nih.gov/pubmed/21029743
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/20888328/abstract/The_effects_of_cannabinoid_drugs_on_abnormal_involuntary_movements_in_dyskinetic_and_non_dyskinetic_6_hydroxydopamine_lesioned_rats_
Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors (abst–2011) http://www.neurobiologyofaging.org/article/S0197-4580%2809%2900116-X/abstract
top
The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273613/
Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24140894
The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273613/
Striatal Molecular Signature of Subchronic Subthalamic Nucleus High Frequency  Stimulation in Parkinsonian Rat (full–2013)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617149/
The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and
cytological preservation in a rat model of Parkinson’s disease and L-DOPA-induced
dyskinesia (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24196024
Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a
mouse model of Parkinson´s disease (abst–2013)  http://www.ncbi.nlm.nih.gov/pubmed/24140894
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology (full–2014) http://www.neurology.org/content/82/17/1556.long
Cannabinoids: New Promising Agents in the Treatment of Neurological Diseases (full–2014) http://www.mdpi.com/1420-3049/19/11/18781/htm
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25486547
The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and
ERK1/2 phosphorylation in 6-OHDA-lesioned rats (full–2014)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226453/
Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24599755
Anandamide attenuates haloperidol-induced vacuous chewing movements in rats (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24747871
The therapeutic potential of cannabinoids for movement disorders (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25649017
Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26059564
Molecular Targets of Cannabidiol in Neurological Disorders (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604182/
Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in
macaques: changes following experimental parkinsonism (full–2015)  http://link.springer.com/article/10.1007/s00429-014-0823-8
Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics (abst–2015) http://link.springer.com/article/10.1007/s13311-015-0376-4
Cannabinoids for the Treatment of Movement Disorders (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26206230
Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats (full–2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00343/full
Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action (abst–2016)  https://www.researchgate.net/publication/304669756_Coadministration_of_cannabidiol_and_capsazepine_ reduces_L-DOPA-induced_dyskinesia_in_mice_Possible_mechanism_of_action
Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal
genes in Parkinson model rats (abst–2017)  http://www.sciencedirect.com/science/article/pii/S0168010217300639
Receptor-heteromer mediated regulation of endocannabinoid signaling in activated
microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer’s disease and
levodopa-induced dyskinesia (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28843453


DYSPEPSIA
Achalasia, status post myotomy (case report–undated) http://cannabisclinicians.org/view-all-case-reports/entry/597/?pagenum=2
Increased Cerebral Cannabinoid-1 Receptor Availability Is a Stable Feature of Functional Dyspepsia: A [F]MK-9470 PET Study (full–2015)  http://www.karger.com/Article/FullText/375454
The long-term functional consequences of acute infectious diarrhea (abst–2015) 
http://www.ncbi.nlm.nih.gov/pubmed/26628101
Association between cerebral cannabinoid 1 receptor availability and body mass index in patients with food intake disorders and healthy subjects: a [(18)F]MK-9470 PET study (full–2016) http://www.nature.com/tp/journal/v6/n7/full/tp2016118a.html
The development of functional gastrointestinal diseases: Genetic aspects (abst–2017)  https://www.ncbi.nlm.nih.gov/pubmed/28635880
top


DYSTONIA*+
Information for Health Care Professionals- Marihuana (marijuana, cannabis) dried plant  for administration by ingestion or other means (Health Canada) (full–2010)  http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php
Dronabinol for the treatment of unspecific pain, restlessness and spasticity in neuropaediatrics (abst–2010) https://www.thieme-connect.com/ejournals/abstract/10.1055/s-0030-1265622
Tardive Dystonia and the Use of Cannabis (letter/forum repost–2010) http://www.420magazine.com/forums/dystonia/169902-tardive-dystonia-use-cannabis.html
Effects of cannabinoid CB(1) receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21029743
Medical cannabis: the opportunity versus the temptation (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/22352284
Early exposure to Environmental enrichment alters the expression of genes of the  endocannabinoid system (abst–2011)  http://www.unboundmedicine.com/medline/ebm/record/21419109/abstract/Early_exposure_to_Environmental_enrichment_alters_the_expression_of_genes_of_the_endocannabinoid_system_
The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and  cytological preservation in a rat model of Parkinson’s disease and L-DOPA-induced  dyskinesia (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24196024
Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia (full–2015) http://onlinelibrary.wiley.com/doi/10.1111/bph.13215/full
Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604174/
Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice (abst–2016) http://www.sciencedirect.com/science/article/pii/S1043661816302663
MEDICAL CANNABIS (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27215115
Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3 (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27717809
Altered striatal endocannabinoid signaling in a transgenic mouse model of  spinocerebellar ataxia type-3 (full–2017)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5407801/
Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in  R6/2 Mice, an Experimental Model of Huntington’s Disease (full–2017)  http://www.mdpi.com/1422-0067/18/4/684/htm
A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders (full–2017) http://www.cpn.or.kr/journal/view.html?volume=15&number=4&spage=301


Advertisements